| Year |
Citation |
Score |
| 2024 |
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301214. PMID 38301187 DOI: 10.1200/JCO.23.01214 |
0.323 |
|
| 2024 |
Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, ... ... Toi M, et al. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients. British Journal of Cancer. PMID 38238427 DOI: 10.1038/s41416-023-02527-0 |
0.479 |
|
| 2024 |
Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Kinukawa N, Watanabe C, Toi M, Saji S. 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan. Breast Cancer (Tokyo, Japan). PMID 38180641 DOI: 10.1007/s12282-023-01532-8 |
0.428 |
|
| 2023 |
Costa L, Kumar R, Villarreal-Garza C, Sinha S, Saini S, Semwal J, Saxsena V, Zamre V, Chintamani C, Ray M, Shimizu C, Gusic LH, Toi M, Lipton A. Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers. Breast (Edinburgh, Scotland). 73: 103623. PMID 38219460 DOI: 10.1016/j.breast.2023.103623 |
0.354 |
|
| 2023 |
Yamaguchi A, Kawaguchi K, Kawanishi K, Maeshima Y, Nakakura A, Kataoka TR, Takahara S, Nakagawa S, Yonezawa A, Takada M, Kawashima M, Kawaguchi-Sakita N, Kotake T, Suzuki E, Shimizu H, ... ... Toi M, et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Research and Treatment. PMID 38123790 DOI: 10.1007/s10549-023-07163-z |
0.42 |
|
| 2023 |
Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Annual report of the Japanese Breast Cancer Registry for 2019. Breast Cancer (Tokyo, Japan). PMID 38044372 DOI: 10.1007/s12282-023-01526-6 |
0.431 |
|
| 2023 |
García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, et al. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE study. European Journal of Cancer (Oxford, England : 1990). 196: 113420. PMID 38000218 DOI: 10.1016/j.ejca.2023.113420 |
0.361 |
|
| 2023 |
Li W, Kawaguchi K, Tanaka S, He C, Maeshima Y, Suzuki E, Toi M. Cellular senescence triggers intracellular acidification and lysosomal pH alkalinized via ATP6AP2 attenuation in breast cancer cells. Communications Biology. 6: 1147. PMID 37993606 DOI: 10.1038/s42003-023-05433-6 |
0.425 |
|
| 2023 |
Nishikawa Y, Agatsuma N, Utsumi T, Funakoshi T, Mori Y, Nakamura Y, Hoshino N, Horimatsu T, Saito T, Kashihara S, Fukuyoshi J, Goto R, Toi M, Takahashi Y, Nakayama T. Medical care costs according to the stage and subtype of breast cancer in a municipal setting: a case study of Hachioji City, Japan. Breast Cancer (Tokyo, Japan). PMID 37982959 DOI: 10.1007/s12282-023-01517-7 |
0.359 |
|
| 2023 |
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martín M. Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37889120 DOI: 10.1158/1078-0432.CCR-22-3573 |
0.36 |
|
| 2023 |
Kuo SH, Tseng LM, Chen ST, Sagara Y, Chang YC, Yeh HT, Kuo YL, Hung CC, Lu TP, Lee YH, Toi M, Huang CS. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). Bmc Cancer. 23: 865. PMID 37710198 DOI: 10.1186/s12885-023-11291-6 |
0.392 |
|
| 2023 |
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, ... ... Toi M, et al. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Research and Treatment. 202: 485-496. PMID 37676450 DOI: 10.1007/s10549-023-07099-4 |
0.385 |
|
| 2023 |
Toi M, Aruga T. SERDs for primary breast cancer. The Lancet. Oncology. 24: 947-949. PMID 37657466 DOI: 10.1016/S1470-2045(23)00291-7 |
0.501 |
|
| 2023 |
Liu L, Kawashima M, Sugimoto M, Sonomura K, Pu F, Li W, Takeda M, Goto T, Kawaguchi K, Sato TA, Toi M. Discovery of lipid profiles in plasma-derived extracellular vesicles as biomarkers for breast cancer diagnosis. Cancer Science. PMID 37608343 DOI: 10.1111/cas.15935 |
0.453 |
|
| 2023 |
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, ... ... Toi M, et al. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06). Cancer Medicine. PMID 37525895 DOI: 10.1002/cam4.6390 |
0.372 |
|
| 2023 |
Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, Chigusa Y, Kawai M, Sawada M, Inoue T, Takeuchi Y, Maeda H, Baba S, Shiozawa Y, Saiki R, ... ... Toi M, et al. Evolutionary histories of breast cancer and related clones. Nature. PMID 37495687 DOI: 10.1038/s41586-023-06333-9 |
0.448 |
|
| 2023 |
Kobayashi K, Masuda N, Mizuno T, Miura K, Tokuda Y, Yoshinami T, Kawaguchi H, Ohtani S, Saeki T, Toi M, Takeuchi M, Ito Y. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). Breast Cancer Research and Treatment. PMID 37480384 DOI: 10.1007/s10549-023-07030-x |
0.422 |
|
| 2023 |
Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, Jinno H, Saji S, Toi M. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Research and Treatment. PMID 37479943 DOI: 10.1007/s10549-023-07022-x |
0.309 |
|
| 2023 |
Ohashi A, Kataoka M, Iima M, Honda M, Ota R, Urushibata Y, Dominik Nickel M, Toi M, Zackrisson S, Nakamoto Y. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI. European Radiology. PMID 37286791 DOI: 10.1007/s00330-023-09730-w |
0.46 |
|
| 2023 |
Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Torii M, Yakami M, Isoda H, Takakura K, Morita S, Takada M, Toi M, Nakamoto Y. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound. Annals of Nuclear Medicine. PMID 37280410 DOI: 10.1007/s12149-023-01846-9 |
0.448 |
|
| 2023 |
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine. 388: 2058-2070. PMID 37256976 DOI: 10.1056/NEJMoa2214131 |
0.394 |
|
| 2023 |
Yamada Y, Simon R, Iwane K, Nakanishi Y, Takeuchi Y, Yoshizawa A, Takada M, Toi M, Haga H, Marx A, Sauter G. An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9. Bmc Cancer. 23: 438. PMID 37179317 DOI: 10.1186/s12885-023-10949-5 |
0.513 |
|
| 2023 |
Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer C, Tutt A. Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer (Tokyo, Japan). PMID 37171785 DOI: 10.1007/s12282-023-01468-z |
0.388 |
|
| 2023 |
He C, Konishi R, Harata A, Nakamura Y, Mizuno R, Yoda M, Toi M, Kawaguchi K, Kawaoka S. Serum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model. Frontiers in Immunology. 14: 1097788. PMID 36817472 DOI: 10.3389/fimmu.2023.1097788 |
0.355 |
|
| 2023 |
Vandenbon A, Mizuno R, Konishi R, Onishi M, Masuda K, Kobayashi Y, Kawamoto H, Suzuki A, He C, Nakamura Y, Kawaguchi K, Toi M, Shimizu M, Tanaka Y, Suzuki Y, et al. Murine breast cancers disorganize the liver transcriptome in a zonated manner. Communications Biology. 6: 97. PMID 36694005 DOI: 10.1038/s42003-023-04479-w |
0.365 |
|
| 2023 |
Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast Cancer (Tokyo, Japan). PMID 36689066 DOI: 10.1007/s12282-023-01436-7 |
0.389 |
|
| 2022 |
Nakayama Y, Hanada M, Koda H, Sugimoto M, Takada M, Toi M. Breast cancer detection using volatile compound profiles in exhaled breath via selected ion-flow tube mass spectrometry. Journal of Breath Research. 17. PMID 36541460 DOI: 10.1088/1752-7163/aca696 |
0.344 |
|
| 2022 |
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study. Japanese Journal of Clinical Oncology. PMID 36484305 DOI: 10.1093/jjco/hyac184 |
0.322 |
|
| 2022 |
Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Fujimoto K, Sugie T, Toi M, Nakamoto Y. Reproducibility assessment of uptake on dedicated breast PET for noise discrimination. Annals of Nuclear Medicine. PMID 36434200 DOI: 10.1007/s12149-022-01809-6 |
0.328 |
|
| 2022 |
Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, ... ... Toi M, et al. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers. Cancer Medicine. PMID 36345163 DOI: 10.1002/cam4.5430 |
0.386 |
|
| 2022 |
Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, Wei R, Sapunar F, Grimes BR, Nabinger SC, Johnston SRD. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. The Oncologist. PMID 36342342 DOI: 10.1093/oncolo/oyac234 |
0.411 |
|
| 2022 |
Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer. Medical Oncology (Northwood, London, England). 39: 208. PMID 36175677 DOI: 10.1007/s12032-022-01782-0 |
0.366 |
|
| 2022 |
Toi M, Huang CS, Im YH, Sohn J, Zhang W, Sakaguchi S, Haddad N, van Hal G, Sledge GW. Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall Survival from MONARCH 2. Cancer Science. PMID 36168844 DOI: 10.1111/cas.15600 |
0.349 |
|
| 2022 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. PMID 36166110 DOI: 10.1007/s10147-022-02237-2 |
0.409 |
|
| 2022 |
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, et al. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Frontiers in Oncology. 12: 886831. PMID 36132153 DOI: 10.3389/fonc.2022.886831 |
0.361 |
|
| 2022 |
Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. Breast Cancer (Tokyo, Japan). PMID 36057014 DOI: 10.1007/s12282-022-01399-1 |
0.397 |
|
| 2022 |
Honda M, Iima M, Kataoka M, Fukushima Y, Ota R, Ohashi A, Toi M, Nakamoto Y. Biomarkers Predictive of Distant Disease-free Survival Derived from Diffusion-weighted Imaging of Breast Cancer. Magnetic Resonance in Medical Sciences : Mrms : An Official Journal of Japan Society of Magnetic Resonance in Medicine. PMID 35922924 DOI: 10.2463/mrms.mp.2022-0060 |
0.375 |
|
| 2022 |
Velaga R, Tanaka S, Toi M. Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours. Cancer Drug Resistance (Alhambra, Calif.). 5: 487-497. PMID 35800379 DOI: 10.20517/cdr.2022.10 |
0.45 |
|
| 2022 |
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, ... ... Toi M, et al. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). Cancer Science. PMID 35754298 DOI: 10.1111/cas.15474 |
0.414 |
|
| 2022 |
Paul AM, George B, Saini S, Pillai MR, Toi M, Costa L, Kumar R. Delineation of Pathogenomic Insights of Breast Cancer in Young Women. Cells. 11. PMID 35741056 DOI: 10.3390/cells11121927 |
0.41 |
|
| 2022 |
Honda M, Kataoka M, Iima M, Ota R, Ohashi A, Kishimoto AO, Miyake KK, Nickel MD, Yamada Y, Toi M, Nakamoto Y. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography (Ann Arbor, Mich.). 8: 1522-1533. PMID 35736873 DOI: 10.3390/tomography8030125 |
0.415 |
|
| 2022 |
Kumar R, Abreu C, Toi M, Saini S, Casimiro S, Arora A, Paul AM, Velaga R, Rameshwar P, Lipton A, Gupta S, Costa L. Oncobiology and treatment of breast cancer in young women. Cancer Metastasis Reviews. PMID 35488982 DOI: 10.1007/s10555-022-10034-6 |
0.438 |
|
| 2022 |
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, ... ... Toi M, et al. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. Bmc Medicine. 20: 136. PMID 35462552 DOI: 10.1186/s12916-022-02332-1 |
0.445 |
|
| 2022 |
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, ... ... Toi M, et al. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer (Tokyo, Japan). PMID 35460066 DOI: 10.1007/s12282-022-01357-x |
0.387 |
|
| 2022 |
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, ... ... Toi M, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. The Lancet. Oncology. 23: 636-649. PMID 35405087 DOI: 10.1016/S1470-2045(22)00196-6 |
0.403 |
|
| 2022 |
Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. Cancer Management and Research. 14: 1179-1194. PMID 35342308 DOI: 10.2147/CMAR.S348591 |
0.406 |
|
| 2022 |
van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer (Oxford, England : 1990). 166: 185-201. PMID 35305453 DOI: 10.1016/j.ejca.2022.02.003 |
0.359 |
|
| 2022 |
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, ... ... Toi M, et al. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. Japanese Journal of Clinical Oncology. PMID 35296894 DOI: 10.1093/jjco/hyac022 |
0.352 |
|
| 2022 |
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Clinical Significance of and Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35121623 DOI: 10.1158/1078-0432.CCR-21-3276 |
0.352 |
|
| 2021 |
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100896. PMID 34890214 DOI: 10.1200/JCO.21.00896 |
0.378 |
|
| 2021 |
Masuda N, Kosaka N, Iwata H, Toi M. Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data. International Journal of Clinical Oncology. 26: 2179-2193. PMID 34698970 DOI: 10.1007/s10147-021-02013-8 |
0.426 |
|
| 2021 |
Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, ... Toi M, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer (Tokyo, Japan). PMID 34665435 DOI: 10.1007/s12282-021-01307-z |
0.396 |
|
| 2021 |
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 34661821 DOI: 10.1007/s12282-021-01295-0 |
0.393 |
|
| 2021 |
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, ... ... Toi M, et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Research and Treatment. PMID 34554370 DOI: 10.1007/s10549-021-06396-0 |
0.398 |
|
| 2021 |
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Research : Bcr. 23: 87. PMID 34425869 DOI: 10.1186/s13058-021-01463-2 |
0.308 |
|
| 2021 |
Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34376533 DOI: 10.1158/1078-0432.CCR-20-4685 |
0.363 |
|
| 2021 |
Miyake KK, Kataoka M, Ishimori T, Matsumoto Y, Torii M, Takada M, Satoh Y, Kubota K, Satake H, Yakami M, Isoda H, Ikeda DM, Toi M, Nakamoto Y. A Proposed Dedicated Breast PET Lexicon: Standardization of Description and Reporting of Radiotracer Uptake in the Breast. Diagnostics (Basel, Switzerland). 11. PMID 34359350 DOI: 10.3390/diagnostics11071267 |
0.369 |
|
| 2021 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. PMID 34043103 DOI: 10.1007/s10147-021-01940-w |
0.409 |
|
| 2021 |
Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M, Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, ... ... Toi M, et al. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Cancer Science. PMID 34036661 DOI: 10.1111/cas.14986 |
0.389 |
|
| 2021 |
Itou J, Nakamura A, Hokazono H, Toi M. Supplementation with Fermented Barley Extract Prevents Mammary Epithelial Cell Invasion in an Early Breast Cancer Model. Acta Histochemica Et Cytochemica. 54: 73-78. PMID 34012179 DOI: JST.JSTAGE/ahc/20-00029 |
0.443 |
|
| 2021 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. 26: 1229-1236. PMID 33891194 DOI: 10.1007/s10147-021-01920-0 |
0.411 |
|
| 2021 |
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J, Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW, ... Toi M, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer (Tokyo, Japan). PMID 33797023 DOI: 10.1007/s12282-021-01239-8 |
0.329 |
|
| 2021 |
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003639. PMID 33793299 DOI: 10.1200/JCO.20.03639 |
0.405 |
|
| 2021 |
Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, ... ... Toi M, et al. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Research and Treatment. PMID 33763789 DOI: 10.1007/s10549-021-06184-w |
0.447 |
|
| 2021 |
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001204. PMID 33539215 DOI: 10.1200/JCO.20.01204 |
0.356 |
|
| 2021 |
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. PMID 33392835 DOI: 10.1007/s10549-020-06029-y |
0.323 |
|
| 2021 |
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 22: 74-84. PMID 33387497 DOI: 10.1016/S1470-2045(20)30534-9 |
0.457 |
|
| 2020 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Ohtani S, Shimizu C, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. Breast Cancer (Tokyo, Japan). PMID 33085032 DOI: 10.1007/s12282-020-01162-4 |
0.33 |
|
| 2020 |
Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, ... ... Toi M, et al. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Communications Biology. 3: 578. PMID 33067557 DOI: 10.1038/s42003-020-01301-9 |
0.358 |
|
| 2020 |
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002514. PMID 32954927 DOI: 10.1200/JCO.20.02514 |
0.413 |
|
| 2020 |
Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Correction to: Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism. 8: 18. PMID 32789015 DOI: 10.1186/s40170-020-00224-7 |
0.645 |
|
| 2020 |
Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, ... ... Toi M, et al. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer (Tokyo, Japan). PMID 32715420 DOI: 10.1007/s12282-020-01138-4 |
0.415 |
|
| 2020 |
Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism. 8: 13. PMID 32647572 DOI: 10.1186/S40170-020-00219-4 |
0.642 |
|
| 2020 |
Chow LWC, Lie EF, Toi M. Advances in EGFR/HER2-directed clinical research on breast cancer. Advances in Cancer Research. 147: 375-428. PMID 32593406 DOI: 10.1016/bs.acr.2020.04.009 |
0.429 |
|
| 2020 |
Lin X, Matsumoto Y, Nakakimura T, Ono K, Umeoka S, Torii M, Yoshibayashi H, Toi M. Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review. Surgical Case Reports. 6: 143. PMID 32562013 DOI: 10.1186/s40792-020-00905-x |
0.413 |
|
| 2020 |
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib Plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. The Oncologist. PMID 32536013 DOI: 10.1634/theoncologist.2020-0084 |
0.333 |
|
| 2020 |
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chinese Clinical Oncology. 9: 32. PMID 32527117 DOI: 10.21037/cco-20-123 |
0.361 |
|
| 2020 |
Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, Hashigaki S, Muramatsu Y, Umeyama Y, Toi M. Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. Cancer Medicine. PMID 32420697 DOI: 10.1002/cam4.3091 |
0.346 |
|
| 2020 |
Tanaka S, Ishii T, Sato F, Toi M, Itou J. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. Biochemical and Biophysical Research Communications. PMID 32201082 DOI: 10.1016/j.bbrc.2020.03.042 |
0.353 |
|
| 2020 |
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, ... ... Toi M, et al. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Research and Treatment. PMID 32170634 DOI: 10.1007/s10549-020-05590-w |
0.311 |
|
| 2020 |
Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, ... ... Toi M, et al. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer (Tokyo, Japan). PMID 32060785 DOI: 10.1007/S12282-020-01057-4 |
0.373 |
|
| 2020 |
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist. 25: e243-e251. PMID 32043763 DOI: 10.1634/theoncologist.2019-0551 |
0.323 |
|
| 2020 |
Itou J, Takahashi R, Sasanuma H, Tsuda M, Morimoto S, Matsumoto Y, Ishii T, Sato F, Takeda S, Toi M. Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition. Iscience. 23: 100821. PMID 31978754 DOI: 10.1016/j.isci.2020.100821 |
0.402 |
|
| 2020 |
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, ... ... Toi M, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Research and Treatment. PMID 31953696 DOI: 10.1007/s10549-020-05524-6 |
0.383 |
|
| 2020 |
Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Japanese Journal of Clinical Oncology. 50: 3-11. PMID 31821506 DOI: 10.1093/jjco/hyz119 |
0.308 |
|
| 2020 |
Honda M, Kataoka M, Onishi N, Iima M, Ohashi A, Kanao S, Nickel MD, Toi M, Togashi K. New parameters of ultrafast dynamic contrast-enhanced breast MRI using compressed sensing. Journal of Magnetic Resonance Imaging : Jmri. 51: 164-174. PMID 31215107 DOI: 10.1002/jmri.26838 |
0.346 |
|
| 2019 |
Shibata T, Watari K, Kawahara A, Sudo T, Hattori S, Murakami Y, Izumi H, Itou J, Toi M, Akiba J, Akagi Y, Tanaka M, Kuwano M, Ono M. Targeting phosphorylation of Y-box binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance. Molecular Cancer Therapeutics. PMID 31879363 DOI: 10.1158/1535-7163.MCT-19-0690 |
0.395 |
|
| 2019 |
Kawashima M, Tokiwa M, Nishimura T, Kawata Y, Sugimoto M, Kataoka TR, Sakurai T, Iwaisako K, Suzuki E, Hagiwara M, Harris AL, Toi M. High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. British Journal of Cancer. PMID 31819188 DOI: 10.1038/s41416-019-0662-8 |
0.516 |
|
| 2019 |
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer (Tokyo, Japan). PMID 31811519 DOI: 10.1007/s12282-019-01029-3 |
0.328 |
|
| 2019 |
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. Jama Oncology. PMID 31563959 DOI: 10.1001/jamaoncol.2019.4782 |
0.376 |
|
| 2019 |
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. PMID 31318460 DOI: 10.1002/cncr.32392 |
0.362 |
|
| 2019 |
Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Ishii T, Sato F, Toi M, Itou J. In silico analysis-based identification of the target residue of integrin α6 for metastasis inhibition of basal-like breast cancer. Genes to Cells : Devoted to Molecular & Cellular Mechanisms. PMID 31295752 DOI: 10.1111/gtc.12714 |
0.334 |
|
| 2019 |
Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiation Oncology (London, England). 14: 121. PMID 31291997 DOI: 10.1186/s13014-019-1327-8 |
0.353 |
|
| 2019 |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Bmc Cancer. 19: 620. PMID 31234810 DOI: 10.1186/s12885-019-5831-x |
0.345 |
|
| 2019 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 31168692 DOI: 10.1007/s12282-019-00984-1 |
0.416 |
|
| 2019 |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Bmc Cancer. 19: 517. PMID 31146717 DOI: 10.1186/s12885-019-5687-0 |
0.332 |
|
| 2019 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 31127500 DOI: 10.1007/s12282-019-00970-7 |
0.348 |
|
| 2019 |
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, ... Toi M, et al. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology. 1-19. PMID 31125276 DOI: 10.1200/JGO.18.00173 |
0.416 |
|
| 2019 |
Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Annals of Nuclear Medicine. PMID 31115856 DOI: 10.1007/s12149-019-01364-7 |
0.342 |
|
| 2019 |
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Insights Into Breast Cancer in the East vs the West: A Review. Jama Oncology. PMID 31095268 DOI: 10.1001/jamaoncol.2019.0620 |
0.428 |
|
| 2019 |
Takada M, Toi M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. International Journal of Clinical Oncology. 24: 608-613. PMID 30982153 DOI: 10.1007/s10147-019-01448-4 |
0.481 |
|
| 2019 |
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. Esmo Open. 4: e000476. PMID 30962956 DOI: 10.1136/esmoopen-2018-000476 |
0.397 |
|
| 2019 |
Benson JR, Jatoi I, Toi M. Surgical management of multiple ipsilateral breast cancers. Future Oncology (London, England). PMID 30924355 DOI: 10.2217/fon-2019-0028 |
0.425 |
|
| 2019 |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M. Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. International Journal of Molecular Sciences. 20. PMID 30813476 DOI: 10.3390/ijms20040984 |
0.311 |
|
| 2019 |
Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M. Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer : Basic and Clinical Research. 13: 1178223418825135. PMID 30733627 DOI: 10.1177/1178223418825135 |
0.426 |
|
| 2018 |
Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 40: 1010428318811025. PMID 30841783 DOI: 10.1177/1010428318811025 |
0.321 |
|
| 2018 |
Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M. Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. Oncotarget. 9: 37216-37228. PMID 30647855 DOI: 10.18632/oncotarget.26469 |
0.364 |
|
| 2018 |
Shiina T, Toi M, Yagi T. Development and clinical translation of photoacoustic mammography. Biomedical Engineering Letters. 8: 157-165. PMID 30603200 DOI: 10.1007/s13534-018-0070-7 |
0.358 |
|
| 2018 |
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, ... ... Toi M, et al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. International Journal of Clinical Oncology. PMID 30515674 DOI: 10.1007/s10147-018-1353-9 |
0.33 |
|
| 2018 |
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proceedings of the National Academy of Sciences of the United States of America. PMID 30352856 DOI: 10.1073/Pnas.1803177115 |
0.371 |
|
| 2018 |
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Breast Cancer (Tokyo, Japan). PMID 30317464 DOI: 10.1007/s12282-018-0920-2 |
0.37 |
|
| 2018 |
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Research and Treatment. 172: 611-618. PMID 30194511 DOI: 10.1007/s10549-018-4958-9 |
0.393 |
|
| 2018 |
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, ... ... Toi M, et al. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Japanese Journal of Clinical Oncology. PMID 30020510 DOI: 10.1093/jjco/hyy097 |
0.361 |
|
| 2018 |
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, ... ... Toi M, et al. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. Breast Cancer : Basic and Clinical Research. 12: 1178223418786243. PMID 30013356 DOI: 10.1177/1178223418786243 |
0.428 |
|
| 2018 |
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, ... ... Toi M, et al. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Photoacoustics. 11: 6-13. PMID 30003041 DOI: 10.1016/j.pacs.2018.06.002 |
0.483 |
|
| 2018 |
Kiso M, Tanaka S, Saji S, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. International Journal of Cancer. PMID 29971782 DOI: 10.1002/ijc.31645 |
0.395 |
|
| 2018 |
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Research and Treatment. PMID 29971625 DOI: 10.1007/s10549-018-4873-0 |
0.487 |
|
| 2018 |
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine. PMID 29905023 DOI: 10.1002/cam4.1600 |
0.368 |
|
| 2018 |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Medicine. PMID 29733541 DOI: 10.1002/cam4.1516 |
0.379 |
|
| 2018 |
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute. PMID 29659933 DOI: 10.1093/Jnci/Djy018 |
0.599 |
|
| 2018 |
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Japanese Journal of Clinical Oncology. 48: 410-416. PMID 29590407 DOI: 10.1093/jjco/hyy030 |
0.381 |
|
| 2018 |
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. Esmo Open. 3: e000314. PMID 29531841 DOI: 10.1136/esmoopen-2017-000314 |
0.354 |
|
| 2018 |
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, et al. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 3079-3086. PMID 29530933 DOI: 10.1158/1078-0432.CCR-17-3473 |
0.306 |
|
| 2018 |
Kotake T, Toi M. Abemaciclib for the treatment of breast cancer. Expert Opinion On Pharmacotherapy. 19: 517-524. PMID 29522364 DOI: 10.1080/14656566.2018.1448787 |
0.461 |
|
| 2018 |
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif containing 21. The Journal of Biological Chemistry. PMID 29511085 DOI: 10.1074/jbc.RA117.000245 |
0.433 |
|
| 2018 |
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. European Radiology. 28: 3194-3203. PMID 29460074 DOI: 10.1007/s00330-017-5297-7 |
0.401 |
|
| 2018 |
Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K. Impact of physiological hormonal fluctuations on F-fluorodeoxyglucose uptake in breast cancer. Breast Cancer Research and Treatment. 169: 437-446. PMID 29423901 DOI: 10.1007/s10549-018-4711-4 |
0.32 |
|
| 2018 |
Itou J, Tsukihara H, Nukatsuka M, Toi M, Takechi T. 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer Medicine. 7: 463-470. PMID 29356434 DOI: 10.1002/cam4.1265 |
0.316 |
|
| 2018 |
Matsumoto Y, Itou J, Sato F, Toi M. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. Cancer Medicine. PMID 29356399 DOI: 10.1002/cam4.1296 |
0.404 |
|
| 2018 |
Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M. Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. Breast (Edinburgh, Scotland). 38: 114-119. PMID 29310035 DOI: 10.1016/j.breast.2017.12.017 |
0.483 |
|
| 2017 |
Tanaka S, Ueno T, Ishiguro H, Morita S, Toi M. The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. Npj Precision Oncology. 1: 6. PMID 29872695 DOI: 10.1038/s41698-017-0006-1 |
0.332 |
|
| 2017 |
Toi M, Masuda N, Lee SJ. Capecitabine for primary breast cancer. Oncotarget. 8: 110739-110740. PMID 29340011 DOI: 10.18632/oncotarget.22990 |
0.502 |
|
| 2017 |
Chow LW, Morita S, Chow CY, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict value. Endocrine-Related Cancer. PMID 29158285 DOI: 10.1530/ERC-17-0396 |
0.308 |
|
| 2017 |
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study. Current Medical Research and Opinion. 1-16. PMID 29095648 DOI: 10.1080/03007995.2017.1400426 |
0.332 |
|
| 2017 |
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017756155. PMID 28968163 DOI: 10.1200/JCO.2017.75.6155 |
0.343 |
|
| 2017 |
Sagara Y, Julia W, Golshan M, Toi M. Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma of Breast. Frontiers in Oncology. 7: 192. PMID 28894698 DOI: 10.3389/fonc.2017.00192 |
0.402 |
|
| 2017 |
Toi M, Masuda N, Ohashi Y. Adjuvant Capecitabine for Breast Cancer. The New England Journal of Medicine. 377: 791-2. PMID 28834474 DOI: 10.1056/NEJMc1708487 |
0.513 |
|
| 2017 |
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, ... ... Toi M, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England Journal of Medicine. 376: 2147-2159. PMID 28564564 DOI: 10.1056/NEJMoa1612645 |
0.36 |
|
| 2017 |
Onishi N, Kataoka M, Kanao S, Sagawa H, Iima M, Nickel MD, Toi M, Togashi K. Ultrafast dynamic contrast-enhanced mri of the breast using compressed sensing: breast cancer diagnosis based on separate visualization of breast arteries and veins. Journal of Magnetic Resonance Imaging : Jmri. 47: 97-104. PMID 28556576 DOI: 10.1002/jmri.25747 |
0.409 |
|
| 2017 |
Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, et al. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Research : Bcr. 19: 47. PMID 28399902 DOI: 10.1186/s13058-017-0839-0 |
0.398 |
|
| 2017 |
Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016697722. PMID 28375706 DOI: 10.1200/JCO.2016.69.7722 |
0.304 |
|
| 2016 |
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Research : Bcr. 18: 129. PMID 27993161 DOI: 10.1186/s13058-016-0788-z |
0.392 |
|
| 2016 |
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. Biochimica Et Biophysica Acta. PMID 27773610 DOI: 10.1016/j.bbamcr.2016.10.012 |
0.308 |
|
| 2016 |
Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? The Lancet. Oncology. 17: e442-e451. PMID 27733270 DOI: 10.1016/S1470-2045(16)30367-9 |
0.33 |
|
| 2016 |
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. Journal of Radiation Research. PMID 27422931 DOI: 10.1093/jrr/rrw071 |
0.423 |
|
| 2016 |
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, et al. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27091708 DOI: 10.1200/JCO.2015.63.9161 |
0.432 |
|
| 2016 |
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. Oncotarget. PMID 27058625 DOI: 10.18632/oncotarget.8620 |
0.412 |
|
| 2016 |
Li W, Itou J, Tanaka S, Nishimura T, Sato F, Toi M. A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. Experimental Cell Research. PMID 27032575 DOI: 10.1016/j.yexcr.2016.03.023 |
0.395 |
|
| 2016 |
Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, ... Toi M, et al. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. Bmc Cancer. 16: 230. PMID 26984766 DOI: 10.1186/s12885-016-2270-9 |
0.446 |
|
| 2016 |
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer (Tokyo, Japan). 24: 111-120. PMID 26942414 DOI: 10.1007/s12282-016-0682-7 |
0.412 |
|
| 2015 |
Itou J, Tanaka S, Li W, Matsumoto Y, Sato F, Toi M. Data of a fluorescent imaging-based analysis of anti-cancer drug effects on three-dimensional cultures of breast cancer cells. Data in Brief. 5: 429-33. PMID 26958605 DOI: 10.1016/j.dib.2015.09.037 |
0.394 |
|
| 2015 |
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M. Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochemical and Biophysical Research Communications. PMID 26740182 DOI: 10.1016/J.Bbrc.2015.12.114 |
0.321 |
|
| 2015 |
Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging. Plos One. 10: e0139113. PMID 26506106 DOI: 10.1371/journal.pone.0139113 |
0.388 |
|
| 2015 |
Sato F, Toi M. [Molecular targeted therapy and genomic evolution of breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 73: 1364-72. PMID 26281691 |
0.427 |
|
| 2015 |
Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, ... Toi M, et al. Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. Annals of Surgical Oncology. PMID 26275781 DOI: 10.1245/s10434-015-4809-4 |
0.315 |
|
| 2015 |
Ueno T, Utsumi J, Toi M, Shimizu K. Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. Biomed Research International. 2015: 960840. PMID 26171396 DOI: 10.1155/2015/960840 |
0.43 |
|
| 2015 |
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet. Oncology. 16: 816-29. PMID 26092818 DOI: 10.1016/S1470-2045(15)00051-0 |
0.403 |
|
| 2015 |
Sato F, Saji S, Toi M. Genomic tumor evolution of breast cancer. Breast Cancer (Tokyo, Japan). PMID 25998191 DOI: 10.1007/s12282-015-0617-8 |
0.371 |
|
| 2015 |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, et al. Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology (London, England). 11: 1301-5. PMID 25952778 DOI: 10.2217/fon.15.66 |
0.435 |
|
| 2015 |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, et al. Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncology (London, England). 11: 1297-300. PMID 25952777 DOI: 10.2217/fon.15.65 |
0.414 |
|
| 2015 |
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, ... ... Toi M, et al. Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients. International Journal of Clinical Oncology. PMID 25772578 DOI: 10.1007/S10147-015-0814-7 |
0.424 |
|
| 2015 |
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, ... ... Toi M, et al. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. International Journal of Clinical Oncology. PMID 25666483 DOI: 10.1007/s10147-015-0785-8 |
0.408 |
|
| 2015 |
Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. Bmc Cancer. 15: 39. PMID 25655677 DOI: 10.1186/s12885-015-1041-3 |
0.428 |
|
| 2015 |
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, et al. 2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission. Breast Cancer (Tokyo, Japan). 22: 1-4. PMID 25056934 DOI: 10.1007/s12282-014-0550-2 |
0.373 |
|
| 2014 |
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Journal of Translational Medicine. 12: 310. PMID 25421542 DOI: 10.1186/s12967-014-0310-2 |
0.451 |
|
| 2014 |
Sugimoto M, Takada M, Toi M. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. The International Journal of Biological Markers. 29: e372-9. PMID 25096734 DOI: 10.5301/jbm.5000103 |
0.336 |
|
| 2014 |
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology. 15: 580-91. PMID 24742739 DOI: 10.1016/S1470-2045(14)70138-X |
0.305 |
|
| 2014 |
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer (Tokyo, Japan). PMID 24574277 DOI: 10.1007/s12282-014-0524-4 |
0.435 |
|
| 2014 |
Fakhrejahani E, Toi M. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Japanese Journal of Clinical Oncology. 44: 197-207. PMID 24474817 DOI: 10.1093/jjco/hyt201 |
0.421 |
|
| 2014 |
Yamashiro H, Takada M, Nakatani E, Imai S, Yamauchi A, Tsuyuki S, Matsutani Y, Sakata S, Wada Y, Okamura R, Harada T, Tanaka F, Moriguchi Y, Kato H, Higashide S, ... ... Toi M, et al. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. International Journal of Clinical Oncology. 19: 852-62. PMID 24292334 DOI: 10.1007/s10147-013-0643-5 |
0.379 |
|
| 2014 |
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology. 19: 607-13. PMID 24101215 DOI: 10.1007/s10147-013-0614-x |
0.396 |
|
| 2014 |
Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer (Tokyo, Japan). 21: 20-7. PMID 22382811 DOI: 10.1007/s12282-012-0344-3 |
0.311 |
|
| 2014 |
Takuwa H, Ueno T, Ishiguro H, Mikami Y, Kanao S, Takada M, Sugie T, Toi M. A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy Breast Cancer. 21: 504-507. PMID 21526425 DOI: 10.1007/s12282-011-0269-2 |
0.455 |
|
| 2013 |
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer (Tokyo, Japan). PMID 24338638 DOI: 10.1007/s12282-013-0511-1 |
0.437 |
|
| 2013 |
Sugimoto M, Takada M, Toi M. Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2013: 3054-7. PMID 24110372 DOI: 10.1109/EMBC.2013.6610185 |
0.35 |
|
| 2013 |
Kaga C, Takagi A, Kano M, Kado S, Kato I, Sakai M, Miyazaki K, Nanno M, Ishikawa F, Ohashi Y, Toi M. Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer. Cancer Science. 104: 1508-14. PMID 23992486 DOI: 10.1111/cas.12268 |
0.37 |
|
| 2013 |
Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S, Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y. Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study. Current Nutrition and Food Science. 9: 194-200. PMID 23966890 DOI: 10.2174/15734013113099990001 |
0.479 |
|
| 2013 |
Itou J, Matsumoto Y, Yoshikawa K, Toi M. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer. Febs Letters. 587: 3115-21. PMID 23954296 DOI: 10.1016/j.febslet.2013.07.049 |
0.439 |
|
| 2013 |
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The Lancet. Oncology. 14: 933-42. PMID 23932548 DOI: 10.1016/S1470-2045(13)70335-8 |
0.458 |
|
| 2013 |
Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. Cancer Science. 104: 1539-43. PMID 23905924 DOI: 10.1111/cas.12245 |
0.476 |
|
| 2013 |
Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R. Novel insights into breast cancer genetic variance through RNA sequencing. Scientific Reports. 3: 2256. PMID 23884293 DOI: 10.1038/Srep02256 |
0.432 |
|
| 2013 |
Kawashima M, Iwamoto N, Kawaguchi-Sakita N, Sugimoto M, Ueno T, Mikami Y, Terasawa K, Sato TA, Tanaka K, Shimizu K, Toi M. High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer. Cancer Science. 104: 1372-9. PMID 23837649 DOI: 10.1111/cas.12229 |
0.444 |
|
| 2013 |
Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. International Journal of Clinical Oncology. 19: 452-9. PMID 23739924 DOI: 10.1007/s10147-013-0570-5 |
0.364 |
|
| 2013 |
Komuro M, Suzuki K, Kanebako M, Kawahara T, Otoi T, Kitazato K, Inagi T, Makino K, Toi M, Terada H. Novel iontophoretic administration method for local therapy of breast cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 168: 298-306. PMID 23562634 DOI: 10.1016/j.jconrel.2013.03.021 |
0.327 |
|
| 2013 |
Ishiguro H, Saji S, Toi M. [Clinical pharmacology of targeted drug for breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 443-6. PMID 23513881 |
0.393 |
|
| 2013 |
Ohno S, Kuroi K, Toi M. An overview of the Japan Breast Cancer Research Group (JBCRG) activities. Breast Cancer (Tokyo, Japan). 20: 291-5. PMID 23494592 DOI: 10.1007/s12282-012-0420-8 |
0.451 |
|
| 2013 |
Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opinion On Investigational Drugs. 22: 299-307. PMID 23394482 DOI: 10.1517/13543784.2013.766715 |
0.319 |
|
| 2013 |
Masuda N, Toi M, Kuroi K. [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 763-72. PMID 23350501 |
0.407 |
|
| 2013 |
Kitai T, Toi M. [Photoacoustic mammography for the diagnosis of breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 326-30. PMID 23350415 |
0.492 |
|
| 2013 |
Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, Minato N, Toi M, Tanaka Y. Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunology, Immunotherapy : Cii. 62: 677-87. PMID 23151944 DOI: 10.1007/S00262-012-1368-4 |
0.374 |
|
| 2013 |
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International Journal of Clinical Oncology. 18: 590-7. PMID 22585426 DOI: 10.1007/s10147-012-0421-9 |
0.38 |
|
| 2012 |
Chan MS, Wang L, Felizola SJ, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. The International Journal of Biological Markers. 27: e295-304. PMID 23280127 DOI: 10.5301/JBM.2012.10439 |
0.315 |
|
| 2012 |
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, et al. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research and Treatment. 136: 919-26. PMID 23143284 DOI: 10.1007/s10549-012-2333-9 |
0.363 |
|
| 2012 |
Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women. Frontiers in Oncology. 2: 123. PMID 23061041 DOI: 10.3389/fonc.2012.00123 |
0.428 |
|
| 2012 |
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. The Breast Journal. 18: 535-41. PMID 23009222 DOI: 10.1111/tbj.12004 |
0.364 |
|
| 2012 |
Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y, Toi M, Togashi K. Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1534-42. PMID 22933819 DOI: 10.2967/jnumed.111.100958 |
0.423 |
|
| 2012 |
Kitai T, Torii M, Sugie T, Kanao S, Mikami Y, Shiina T, Toi M. Photoacoustic mammography: initial clinical results. Breast Cancer (Tokyo, Japan). 21: 146-53. PMID 22484692 DOI: 10.1007/s12282-012-0363-0 |
0.318 |
|
| 2012 |
Tsuji W, Teramukai S, Ueno M, Toi M, Inamoto T. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer (Tokyo, Japan). 21: 86-95. PMID 22477265 DOI: 10.1007/s12282-012-0358-x |
0.409 |
|
| 2012 |
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. Plos One. 7: e31422. PMID 22384020 DOI: 10.1371/journal.pone.0031422 |
0.357 |
|
| 2012 |
Toi M. [Breast and endocrine tumor-recent progress and future view for treatment of breast cancer-]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 38: 2558. PMID 22315737 |
0.474 |
|
| 2012 |
Ueno T, Emi M, Sato H, Ito N, Muta M, Kuroi K, Toi M. Genome-wide copy number analysis in primary breast cancer. Expert Opinion On Therapeutic Targets. 16: S31-5. PMID 22313367 DOI: 10.1517/14728222.2011.636739 |
0.405 |
|
| 2012 |
Chan MS, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo WT, Chow LW, Suzuki T, Sasano H. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opinion On Therapeutic Targets. 16: S69-78. PMID 22309693 DOI: 10.1517/14728222.2011.628938 |
0.441 |
|
| 2012 |
Takeda K, Kanao S, Okada T, Kataoka M, Ueno T, Toi M, Ishiguro H, Mikami Y, Togashi K. Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. European Journal of Radiology. 81: 2627-31. PMID 22221829 DOI: 10.1016/j.ejrad.2011.12.013 |
0.4 |
|
| 2012 |
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano H, Toi M. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast (Edinburgh, Scotland). 21: 40-5. PMID 21855342 DOI: 10.1016/j.breast.2011.07.015 |
0.39 |
|
| 2011 |
Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. European Journal of Cancer (Oxford, England : 1990). 47: 2537-45. PMID 21741825 DOI: 10.1016/j.ejca.2011.06.027 |
0.427 |
|
| 2011 |
Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ, Toi M. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. European Journal of Cancer (Oxford, England : 1990). 47: 2265-72. PMID 21737256 DOI: 10.1016/j.ejca.2011.06.015 |
0.469 |
|
| 2011 |
Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Japanese Journal of Clinical Oncology. 41: 867-75. PMID 21719750 DOI: 10.1093/jjco/hyr081 |
0.315 |
|
| 2011 |
Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T, Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Science. 102: 1590-6. PMID 21585620 DOI: 10.1111/j.1349-7006.2011.01985.x |
0.402 |
|
| 2011 |
Toi M, Yasui W, Ito H, Tahara E. Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima. Japanese Journal of Clinical Oncology. 41: 924-30. PMID 21565925 DOI: 10.1093/jjco/hyr054 |
0.449 |
|
| 2011 |
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Annals of Surgical Oncology. 18: 2885-92. PMID 21431404 DOI: 10.1245/s10434-011-1666-7 |
0.318 |
|
| 2011 |
Takada M, Toi M. [Surgery for breast cancer -- from radical mastectomy to breast-conserving surgery]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 38: 173-8. PMID 21368479 |
0.444 |
|
| 2011 |
Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M, Kuroi K. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surgery Today. 41: 328-32. PMID 21365411 DOI: 10.1007/s00595-009-4276-2 |
0.377 |
|
| 2011 |
Toi M. [Current organ topics: chemotherapy of breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 37: 2844. PMID 21235089 |
0.453 |
|
| 2011 |
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Science. 102: 858-65. PMID 21231986 DOI: 10.1111/j.1349-7006.2011.01867.x |
0.44 |
|
| 2011 |
Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Research and Treatment. 127: 739-49. PMID 21082239 DOI: 10.1007/s10549-010-1243-y |
0.308 |
|
| 2010 |
Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. Journal of Medical and Dental Sciences. 57: 155-63. PMID 21073134 |
0.455 |
|
| 2010 |
Yamashiro H, Toi M. [Molecular targeted therapy for breast cancer treatment, challenge to cure]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 68: 1854-8. PMID 20954329 |
0.411 |
|
| 2010 |
Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW, Toi M, Sasano H. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Anticancer Research. 30: 3465-72. PMID 20944124 |
0.378 |
|
| 2010 |
Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno E, Ishiguro H, Bando H. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Japanese Journal of Clinical Oncology. 40: i13-18. PMID 20870914 DOI: 10.1093/jjco/hyq122 |
0.508 |
|
| 2010 |
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemotherapy and Pharmacology. 67: 1007-15. PMID 20628744 DOI: 10.1007/s00280-010-1390-1 |
0.348 |
|
| 2010 |
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 116: 3112-8. PMID 20564629 DOI: 10.1002/cncr.25206 |
0.369 |
|
| 2010 |
Kitagawa D, Saji S, Horiguchi S, Satoh Y, Horiguchi K, Toi M, Funata N, Kuroi K. Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy. The Breast Journal. 16: 435-6. PMID 20545937 DOI: 10.1111/j.1524-4741.2010.00943.x |
0.376 |
|
| 2010 |
Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer (Tokyo, Japan). 18: 64-7. PMID 20354831 DOI: 10.1007/s12282-010-0198-5 |
0.348 |
|
| 2010 |
Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clinical Therapeutics. 32: 311-26. PMID 20206789 DOI: 10.1016/j.clinthera.2010.01.029 |
0.37 |
|
| 2010 |
Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. Bmc Cancer. 10: 56. PMID 20178580 DOI: 10.1186/1471-2407-10-56 |
0.373 |
|
| 2010 |
Sugie T, Tanaka Y, Toi M. [New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 2555-9. PMID 20104681 |
0.498 |
|
| 2010 |
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer (Tokyo, Japan). 17: 190-8. PMID 19575284 DOI: 10.1007/s12282-009-0132-x |
0.33 |
|
| 2009 |
Kondo M, Hoshi SL, Toi M. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Japanese Journal of Clinical Oncology. 39: 767-70. PMID 19656807 DOI: 10.1093/jjco/hyp081 |
0.364 |
|
| 2009 |
Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S, Kitagawa D, Funata N, Toi M, Sugihara K, Kuroi K. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncology Reports. 22: 273-8. PMID 19578766 |
0.38 |
|
| 2009 |
Toi M, Sasano H, Ellis MJ. [Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 1035-42. PMID 19542732 |
0.435 |
|
| 2009 |
Noguchi S, Toi M. From standardization to personalization in breast cancer treatment. Breast Cancer (Tokyo, Japan). 16: 241-2. PMID 19350355 DOI: 10.1007/s12282-009-0106-z |
0.459 |
|
| 2009 |
Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 63: 703-6. PMID 19269774 DOI: 10.1016/j.biopha.2009.02.003 |
0.422 |
|
| 2009 |
Toi M, Yamashiro H, Tsuji W. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. Breast Cancer (Tokyo, Japan). 16: 207-18. PMID 19259765 DOI: 10.1007/s12282-009-0096-x |
0.431 |
|
| 2009 |
Takada M, Ishiguro H, Toi M. [Treatment for breast cancer and endocrine neoplasm]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 2344-50. PMID 19117102 |
0.488 |
|
| 2009 |
Toi M. [Breast and endocrine tumor]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 2338. PMID 19117100 |
0.361 |
|
| 2008 |
Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, Kato H, Toi M, Fukushima M. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. Bmc Cancer. 8: 323. PMID 18990247 DOI: 10.1186/1471-2407-8-323 |
0.343 |
|
| 2008 |
Toi M. Novel targeting therapy concept for breast cancer treatment. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 132: 177-9. PMID 18787301 DOI: 10.1254/fpj.132.177 |
0.421 |
|
| 2008 |
Yoshibayashi H, Ishiguro H, Takada M, Takeuchi M, Yamashiro H, Ueno T, Kato H, Yoshikawa K, Kanao S, Yamauchi C, Mikami Y, Toi M. [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 987-90. PMID 18633230 |
0.462 |
|
| 2008 |
Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Anti-Cancer Drugs. 19: 753-9. PMID 18594220 DOI: 10.1097/CAD.0b013e328302eb15 |
0.349 |
|
| 2008 |
Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A. Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. International Journal of Clinical Oncology. 13: 252-6. PMID 18553236 DOI: 10.1007/s10147-007-0748-9 |
0.398 |
|
| 2008 |
Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 111: 13-7. PMID 18514508 DOI: 10.1016/j.jsbmb.2008.04.004 |
0.442 |
|
| 2008 |
Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. International Journal of Clinical Oncology. 13: 3-7. PMID 18307012 DOI: 10.1007/s10147-007-0719-1 |
0.502 |
|
| 2008 |
Chow LW, Yip AY, Loo WT, Toi M. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Letters. 262: 232-8. PMID 18248884 DOI: 10.1016/j.canlet.2007.12.003 |
0.409 |
|
| 2008 |
Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. Oncology. 72: 330-7. PMID 18187954 DOI: 10.1159/000113062 |
0.424 |
|
| 2008 |
Toi M. Long-term outcomes of aromatase inhibition for breast cancer. The Lancet. Oncology. 9: 8-10. PMID 18177815 DOI: 10.1016/S1470-2045(07)70392-3 |
0.39 |
|
| 2008 |
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Research and Treatment. 110: 531-9. PMID 17879158 DOI: 10.1007/s10549-007-9744-z |
0.32 |
|
| 2007 |
Takada M, Toi M. [Primary systemic chemotherapy for breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 34: 1730-4. PMID 18030005 |
0.417 |
|
| 2007 |
Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, Abe O. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. International Journal of Oncology. 31: 899-906. PMID 17786323 |
0.4 |
|
| 2007 |
Kitagawa D, Toi M. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 396-401. PMID 17682183 |
0.428 |
|
| 2007 |
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3198-206. PMID 17545523 DOI: 10.1158/1078-0432.CCR-07-0009 |
0.426 |
|
| 2007 |
Suzuki E, Toi M. Improving the efficacy of trastuzumab in breast cancer. Cancer Science. 98: 767-71. PMID 17428260 DOI: 10.1111/j.1349-7006.2007.00455.x |
0.462 |
|
| 2006 |
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 411-7. PMID 17179098 DOI: 10.1200/JCO.2006.08.1646 |
0.431 |
|
| 2006 |
Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Research and Treatment. 104: 267-75. PMID 17066321 DOI: 10.1007/s10549-006-9416-4 |
0.345 |
|
| 2006 |
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Early breast cancer. International Journal of Clinical Oncology. 11: 108-19. PMID 16622745 DOI: 10.1007/s10147-006-0564-7 |
0.469 |
|
| 2006 |
Suzuki E, Toi M. [Neoadjuvant Chemotherapy in breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 64: 536-9. PMID 16529046 |
0.443 |
|
| 2006 |
Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer (Tokyo, Japan). 13: 49-57. PMID 16518062 DOI: 10.2325/jbcs.13.49 |
0.401 |
|
| 2006 |
Kondo M, Toi M. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan. Expert Review of Anticancer Therapy. 6: 197-204. PMID 16445372 DOI: 10.1586/14737140.6.2.197 |
0.409 |
|
| 2006 |
Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemotherapy and Pharmacology. 21-6. PMID 16273360 DOI: 10.1007/s00280-005-0107-3 |
0.449 |
|
| 2005 |
Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN. Reducing the global breast cancer burden: the importance of patterns of care research. Clinical Breast Cancer. 6: 412-20. PMID 16381624 DOI: 10.3816/CBC.2005.n.045 |
0.33 |
|
| 2005 |
Saji S, Toi M. Aromatase inhibitors and other novel agents in breast cancer treatment. Expert Opinion On Emerging Drugs. 7: 303-19. PMID 15989553 DOI: 10.1517/14728214.7.2.303 |
0.435 |
|
| 2005 |
Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Japanese Journal of Clinical Oncology. 35: 310-5. PMID 15930037 DOI: 10.1093/jjco/hyi090 |
0.451 |
|
| 2005 |
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, et al. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma Breast Cancer. 12: 99-103. PMID 15858439 DOI: 10.2325/jbcs.12.99 |
0.317 |
|
| 2005 |
Toi M, Takebayashi Y, Chow LW. Translational research in breast cancer Breast Cancer. 12: 86-90. PMID 15858437 DOI: 10.2325/jbcs.12.86 |
0.357 |
|
| 2005 |
Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2986-90. PMID 15837752 DOI: 10.1158/1078-0432.CCR-04-2275 |
0.37 |
|
| 2005 |
Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 24: 4531-9. PMID 15806142 DOI: 10.1038/Sj.Onc.1208646 |
0.347 |
|
| 2005 |
Toi M, Bando H, Chow LW. Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 58: 531-5. PMID 15599986 DOI: 10.1016/j.biopha.2003.12.016 |
0.397 |
|
| 2004 |
Nakanishi C, Yamaguchi T, Iijima T, Saji S, Toi M, Mori T, Miyaki M. Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology. 67: 476-9. PMID 15714005 DOI: 10.1159/000082933 |
0.347 |
|
| 2004 |
Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer (Tokyo, Japan). 11: 129-33. PMID 15550858 DOI: 10.1007/BF02968291 |
0.392 |
|
| 2004 |
Yamashiro H, Toyama K, Bando H, Saji S, Toi M. [Trastuzumab treatment for breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 62: 1305-11. PMID 15283148 |
0.486 |
|
| 2004 |
Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder S, Saji S, Hayashi Y, Funata N, Kinoshita J, Murakami S, Ohono S. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. International Journal of Oncology. 25: 397-405. PMID 15254737 |
0.4 |
|
| 2004 |
Kawakita M, Hiramatsu K, Sugimoto M, Takahashi K, Toi M. [Clinical usefulness of urinary diacetylpolyamines as novel tumor markers]. Rinsho Byori. the Japanese Journal of Clinical Pathology. 52: 321-7. PMID 15164599 |
0.305 |
|
| 2004 |
Kawakami M, Saji S, Toi M. [Controversies in endocrine therapy for breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 31: 181-7. PMID 14997748 |
0.357 |
|
| 2004 |
Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis. 6: 121-8. PMID 14739618 DOI: 10.1023/B:AGEN.0000011802.81320.e4 |
0.38 |
|
| 2004 |
Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, Saji S. Current status of antibody therapy for breast cancer. Breast Cancer (Tokyo, Japan). 11: 10-4. PMID 14718785 DOI: 10.1007/BF02967994 |
0.407 |
|
| 2004 |
Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 57: 333-40. PMID 14568227 DOI: 10.1016/s0753-3322(03)00098-2 |
0.405 |
|
| 2004 |
Yamamoto Y, Yamashita J, Toi M, Muta M, Nagai S, Hanai N, Furuya A, Osawa Y, Saji S, Ogawa M. Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. Oncology Reports. 10: 791-6. PMID 12792725 |
0.344 |
|
| 2004 |
Toi M, Bando H, Saji S. Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 9: RA90-5. PMID 12761467 |
0.334 |
|
| 2003 |
Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 57: 463-70. PMID 14637390 |
0.412 |
|
| 2003 |
Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. The Journal of Steroid Biochemistry and Molecular Biology. 86: 443-7. PMID 14623542 |
0.436 |
|
| 2003 |
Kuroi K, Toi M. [Male breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 30: 599-605. PMID 12795089 |
0.461 |
|
| 2003 |
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, et al. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 991-8. PMID 12637462 DOI: 10.1200/JCO.2003.06.014 |
0.418 |
|
| 2003 |
Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Letters. 190: 191-7. PMID 12565174 DOI: 10.1016/s0304-3835(02)00590-6 |
0.35 |
|
| 2003 |
Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer (Tokyo, Japan). 10: 10-4. PMID 12525757 DOI: 10.1007/BF02967619 |
0.347 |
|
| 2002 |
Nakanishi C, Toi M, Saji S, Bando H. [Current indications for mastectomy in patients with breast cancer]. Nihon Geka Gakkai Zasshi. 103: 821-4. PMID 12478859 |
0.387 |
|
| 2002 |
Watanabe T, Sano M, Toi M, Saeki T, Kanda K, Miura S, Inaji H, Sono H, Saeki H, Nishimura R, Fujita Y. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 29: 1211-21. PMID 12146002 |
0.312 |
|
| 2002 |
Tominaga T, Toi M, Ohashi Y, Abe O. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clinical Breast Cancer. 3: 55-64. PMID 12020396 DOI: 10.3816/cbc.2002.n.012 |
0.348 |
|
| 2002 |
Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Japanese Journal of Cancer Research : Gann. 93: 389-96. PMID 11985788 |
0.409 |
|
| 2002 |
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, et al. The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. International Journal of Oncology. 20: 517-25. PMID 11836563 |
0.401 |
|
| 2002 |
Kuroi K, Tanaka C, Bando H, Saji S, Hayashi K, Toi M. [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 29: 55-60. PMID 11816478 |
0.33 |
|
| 2002 |
Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S, Terada K, Sugiyama T, Fukumoto M, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Japanese Journal of Cancer Research : Gann. 93: 70-7. PMID 11802810 DOI: 10.1111/J.1349-7006.2002.Tb01202.X |
0.341 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 36493792 DOI: 10.1016/S1470-2045(22)00694-5 |
0.3 |
|
| 2021 |
Johnston S, O'Shaughnessy J, Martin M, Huober J, Toi M, Sohn J, André VAM, Martin HR, Hardebeck MC, Goetz MP. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. Npj Breast Cancer. 7: 80. PMID 34158513 DOI: 10.1038/s41523-021-00289-7 |
0.299 |
|
| 2010 |
Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K, Tomita M, Eishi Y. Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. Journal of Medical and Dental Sciences. 57: 165-75. PMID 21073135 |
0.298 |
|
| 2017 |
Sugie T, Toi M. Comparison of the Indocyanine Green Fluorescence and Blue Dye Methods for the Detection of Sentinel Lymph Nodes in Early-stage Breast Cancer: A Reply. Annals of Surgical Oncology. 24: 583-584. PMID 29094247 DOI: 10.1245/s10434-017-6187-6 |
0.298 |
|
| 2017 |
Nishimatsu K, Nakamoto Y, Miyake KK, Ishimori T, Kanao S, Toi M, Togashi K. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT. European Journal of Radiology. 90: 138-145. PMID 28583624 DOI: 10.1016/j.ejrad.2017.02.046 |
0.298 |
|
| 2007 |
Masuda N, Toi M, Takatsuka Y, Nakamura S, Iwata H, Ohno S, Kuroi K, Kusama M, Hisamatsu K, Yamazaki K, Eisei S, Sato Y, Kaise H, Kashiwaba M, Iwase H, et al. [Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 34: 1609-15. PMID 17940375 |
0.297 |
|
| 2004 |
Tominaga T, Kimura M, Asaga T, Yoshida M, Awane H, Koyama H, Takatsuka Y, Mitsuyama S, Ikeda T, Ogita M, Aoyama H, Sano M, Abe R, Nishi T, Wada T, ... ... Toi M, et al. 1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial Oncology Reports. 12: 797-803. PMID 15375502 |
0.294 |
|
| 2002 |
Kumagai Y, Toi M, Inoue H. Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. The Lancet. Oncology. 3: 604-10. PMID 12372722 DOI: 10.1016/s1470-2045(02)00874-4 |
0.294 |
|
| 2021 |
Yamaguchi A, Honda M, Ishiguro H, Kataoka M, Kataoka TR, Shimizu H, Torii M, Mori Y, Kawaguchi-Sakita N, Ueno K, Kawashima M, Takada M, Suzuki E, Nakamoto Y, Kawaguchi K, ... Toi M, et al. Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study. Scientific Reports. 11: 10112. PMID 33980938 DOI: 10.1038/s41598-021-89380-4 |
0.292 |
|
| 2023 |
Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer C, Tutt A. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer (Tokyo, Japan). PMID 37005966 DOI: 10.1007/s12282-023-01451-8 |
0.292 |
|
| 2021 |
Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Hae Park I, Im SA, Chen SC, Enatsu S, Turner PK, André VAM, Hardebeck MC, Sakaguchi S, Goetz MP, Sledge GW. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science. PMID 33686753 DOI: 10.1111/cas.14877 |
0.291 |
|
| 2015 |
Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M. An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer. Biochimica Et Biophysica Acta. 1853: 27-40. PMID 25305574 DOI: 10.1016/j.bbamcr.2014.10.004 |
0.29 |
|
| 2015 |
Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. The International Journal of Biological Markers. 30: 0. PMID 25684439 DOI: 10.5301/jbm.5000136 |
0.29 |
|
| 2009 |
Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer (Tokyo, Japan). 17: 199-204. PMID 19649686 DOI: 10.1007/s12282-009-0139-3 |
0.29 |
|
| 2021 |
Nishie M, Suzuki E, Hattori M, Kawaguch K, Kataoka TR, Hirata M, Pu F, Kotake T, Tsuda M, Yamaguchi A, Sugie T, Toi M. Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity. Cancer Immunology, Immunotherapy : Cii. 70: 817-830. PMID 33000417 DOI: 10.1007/s00262-020-02732-3 |
0.289 |
|
| 2019 |
Kinoshita T, Nakayama T, Fukuma E, Inokuchi M, Ishiguro H, Ogo E, Kikuchi M, Jinno H, Yamazaki N, Toi M. Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study. Frontiers in Oncology. 9: 733. PMID 31448235 DOI: 10.3389/fonc.2019.00733 |
0.287 |
|
| 2015 |
Ueshima C, Kataoka TR, Hirata M, Furuhata A, Suzuki E, Toi M, Tsuruyama T, Okayama Y, Haga H. The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion. Cancer Immunology Research. 3: 871-80. PMID 25735953 DOI: 10.1158/2326-6066.CIR-14-0199 |
0.283 |
|
| 2018 |
Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Toi M. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study. Cancer Science. PMID 29345736 DOI: 10.1111/cas.13507 |
0.282 |
|
| 2011 |
Chow LW, Yip AY, Chu WP, Loo WT, Toi M. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. The Journal of Steroid Biochemistry and Molecular Biology. 125: 112-9. PMID 21236344 DOI: 10.1016/j.jsbmb.2010.12.018 |
0.281 |
|
| 2015 |
Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemotherapy and Pharmacology. 76: 739-50. PMID 26254023 DOI: 10.1007/s00280-015-2826-4 |
0.281 |
|
| 2005 |
Okubo I, Kondo M, Toi M, Ochiai T, Miki S. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 32: 351-63. PMID 15791818 |
0.281 |
|
| 2007 |
Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1875-82. PMID 17363544 DOI: 10.1158/1078-0432.CCR-06-1335 |
0.28 |
|
| 2005 |
Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1287-93. PMID 15709200 |
0.28 |
|
| 2015 |
Onishi N, Kanao S, Kataoka M, Iima M, Sakaguchi R, Kawai M, Kataoka TR, Mikami Y, Toi M, Togashi K. Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma. Journal of Magnetic Resonance Imaging : Jmri. 41: 610-5. PMID 24590513 DOI: 10.1002/jmri.24615 |
0.28 |
|
| 2010 |
Chow LW, Toi M. Combat against cancer with science and medicine. Expert Opinion On Investigational Drugs. 19: S3-4. PMID 20374027 DOI: 10.1517/13543781003748475 |
0.278 |
|
| 2013 |
Lertkhachonsuk AA, Yip CH, Khuhaprema T, Chen DS, Plummer M, Jee SH, Toi M, Wilailak S. Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. The Lancet. Oncology. 14: e497-507. PMID 24176569 DOI: 10.1016/S1470-2045(13)70350-4 |
0.278 |
|
| 2017 |
Tanaka Y, Iwasaki M, Murata-Hirai K, Matsumoto K, Hayashi K, Okamura H, Sugie T, Minato N, Morita CT, Toi M. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Scientific Reports. 7: 5987. PMID 28729550 DOI: 10.1038/S41598-017-05553-0 |
0.276 |
|
| 2023 |
Kumar R, Mardones M, Costa L, Saini S, Villarreal-Garza C, Martinez-Cannon BA, Manjunath G, Sinha S, Han Z, Arora A, Ferreira AM, Larsen L, Hairabedian S, Curry T, Borge H, ... ... Toi M, et al. Beyond October, Beyond Pink: A Year-Round Revelation for Women's Breast Health. Journal of Women's Health (2002). PMID 37787652 DOI: 10.1089/jwh.2023.0663 |
0.275 |
|
| 2013 |
Toi M. Acknowledgments - OOTR Annual Conference 2012 Proceedings. The International Journal of Biological Markers. 27: 285. PMID 23334792 DOI: 10.5301/JBM.2013.10605 |
0.274 |
|
| 2019 |
Kawaguchi K, Sakurai M, Yamamoto Y, Suzuki E, Tsuda M, Kataoka TR, Hirata M, Nishie M, Nojiri T, Kumazoe M, Saito K, Toi M. Alteration of specific cytokine expression patterns in patients with breast cancer. Scientific Reports. 9: 2924. PMID 30814616 DOI: 10.1038/s41598-019-39476-9 |
0.274 |
|
| 2014 |
Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer. Ajr. American Journal of Roentgenology. 203: 272-9. PMID 25055259 DOI: 10.2214/AJR.13.11971 |
0.274 |
|
| 2009 |
Ueno T, Toi M. [Biomarker]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 15-20. PMID 19151560 |
0.273 |
|
| 2003 |
Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson JA, Toi M. Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer (Tokyo, Japan). 9: 303-7. PMID 12459710 DOI: 10.1007/BF02967608 |
0.273 |
|
| 2012 |
Takada M, Sugimoto M, Naito Y, Moon HG, Han W, Noh DY, Kondo M, Kuroi K, Sasano H, Inamoto T, Tomita M, Toi M. Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. Bmc Medical Informatics and Decision Making. 12: 54. PMID 22695278 DOI: 10.1186/1472-6947-12-54 |
0.272 |
|
| 2010 |
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Research and Treatment. 120: 639-48. PMID 20151319 DOI: 10.1007/s10549-010-0785-3 |
0.271 |
|
| 2017 |
Kawai M, Kataoka M, Kanao S, Iima M, Onishi N, Ohashi A, Sakaguchi R, Toi M, Togashi K. The Value of Lesion Size as an Adjunct to the BI-RADS-MRI 2013 Descriptors in the Diagnosis of Solitary Breast Masses. Magnetic Resonance in Medical Sciences : Mrms : An Official Journal of Japan Society of Magnetic Resonance in Medicine. PMID 29213007 DOI: 10.2463/mrms.mp.2017-0024 |
0.271 |
|
| 2023 |
Tokunaga E, Miyoshi Y, Dozono K, Kawaguchi T, Toi M. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial. The Oncologist. PMID 37971418 DOI: 10.1093/oncolo/oyad301 |
0.27 |
|
| 2006 |
Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer (Tokyo, Japan). 13: 38-48. PMID 16518061 DOI: 10.2325/jbcs.13.38 |
0.27 |
|
| 2012 |
Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Molecular & Cellular Proteomics : McP. 11: 1741-57. PMID 22964224 DOI: 10.1074/Mcp.M112.019919 |
0.268 |
|
| 2017 |
Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). Cancer Medicine. PMID 29131533 DOI: 10.1002/cam4.1258 |
0.268 |
|
| 2002 |
Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Research. 62: 4849-53. PMID 12208729 |
0.267 |
|
| 2002 |
Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. International Journal of Cancer. 98: 14-8. PMID 11857378 DOI: 10.1002/ijc.10121 |
0.265 |
|
| 2007 |
Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Research and Treatment. 112: 175-87. PMID 18075786 DOI: 10.1007/s10549-007-9842-y |
0.262 |
|
| 2021 |
Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, ... ... Toi M, et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Investigational New Drugs. 39: 217-225. PMID 32833136 DOI: 10.1007/s10637-020-00991-6 |
0.26 |
|
| 2021 |
Iima M, Kataoka M, Honda M, Ohashi A, Ohno Kishimoto A, Ota R, Uozumi R, Urushibata Y, Feiweier T, Toi M, Nakamoto Y. The Rate of Apparent Diffusion Coefficient Change With Diffusion Time on Breast Diffusion-Weighted Imaging Depends on Breast Tumor Types and Molecular Prognostic Biomarker Expression. Investigative Radiology. 56: 501-508. PMID 33660629 DOI: 10.1097/RLI.0000000000000766 |
0.259 |
|
| 2007 |
Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, Weich H, Toi M. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Science. 98: 405-10. PMID 17214745 DOI: 10.1111/j.1349-7006.2007.00402.x |
0.258 |
|
| 2004 |
Kuroi K, Bando H, Saji S, Toi M. Protracted administration of weekly docetaxel in metastatic breast cancer. Oncology Reports. 10: 1479-84. PMID 12883727 |
0.257 |
|
| 2019 |
Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. Magnetic Resonance in Medical Sciences : Mrms : An Official Journal of Japan Society of Magnetic Resonance in Medicine. 18: 200-207. PMID 30416179 DOI: 10.2463/mrms.mp.2018-0015 |
0.256 |
|
| 2003 |
Ogura O, Kanzaki A, Bando H, Ogura T, Toi M, Takebayashi Y. Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic. Cancer Letters. 190: 97-104. PMID 12536082 DOI: 10.1016/S0304-3835(02)00098-8 |
0.255 |
|
| 2024 |
Toi M, Kinoshita T, Benson JR, Jatoi I, Kataoka M, Han W, Yamauchi C, Inamoto T, Takada M. Non-surgical ablation for breast cancer: an emerging therapeutic option. The Lancet. Oncology. 25: e114-e125. PMID 38423057 DOI: 10.1016/S1470-2045(23)00615-0 |
0.255 |
|
| 2012 |
Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis. 15: 141-50. PMID 22212406 DOI: 10.1007/s10456-011-9250-0 |
0.255 |
|
| 2016 |
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, ... ... Toi M, et al. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Science. 107: 189-202. PMID 26919617 DOI: 10.1111/Cas.12857 |
0.254 |
|
| 2022 |
Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, ... ... Toi M, et al. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Scientific Reports. 12: 22397. PMID 36575361 DOI: 10.1038/s41598-022-27048-3 |
0.253 |
|
| 2019 |
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 5: 5. PMID 30675515 DOI: 10.1038/s41523-018-0097-z |
0.252 |
|
| 2020 |
Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y, Kogawa T, Tanaka K, Kotani H, Yasojima H, Ozaki Y, Noguchi E, Miyasita M, Kondo N, Niikura N, ... Toi M, et al. Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer. The Oncologist. PMID 33321004 DOI: 10.1002/onco.13640 |
0.252 |
|
| 2014 |
Fakhrejahani E, Asao Y, Toi M. Tumor microvasculature characteristics studied by image analysis: histologically-driven angiogenic profile. The International Journal of Biological Markers. 29: e204-7. PMID 25041785 DOI: 10.5301/jbm.5000098 |
0.251 |
|
| 2022 |
Najnin RA, Al Mahmud MR, Rahman MM, Takeda S, Sasanuma H, Tanaka H, Murakawa Y, Shimizu N, Akter S, Takagi M, Sunada T, Akamatsu S, He G, Itou J, Toi M, et al. ATM suppresses c-Myc overexpression in the mammary epithelium in response to estrogen. Cell Reports. 42: 111909. PMID 36640339 DOI: 10.1016/j.celrep.2022.111909 |
0.25 |
|
| 2005 |
Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. The Lancet. Oncology. 6: 158-66. PMID 15737832 DOI: 10.1016/S1470-2045(05)01766-3 |
0.248 |
|
| 2017 |
Torii M, Fukui T, Inoue M, Kanao S, Umetani K, Shirai M, Inagaki T, Tsuchimochi H, Pearson JT, Toi M. Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using SPring-8 synchrotron radiation microangiography. Journal of Synchrotron Radiation. 24: 1039-1047. PMID 28862627 DOI: 10.1107/S1600577517008372 |
0.248 |
|
| 2020 |
Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Yanagita Y, Takano T, Shimizu S, Toi M. Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer Medicine. 9: 9246-9255. PMID 33094919 DOI: 10.1002/cam4.3528 |
0.246 |
|
| 2018 |
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. Breast Cancer (Tokyo, Japan). PMID 29744670 DOI: 10.1007/s12282-018-0868-2 |
0.245 |
|
| 2017 |
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 141-148. PMID 28056202 DOI: 10.1200/JCO.2016.67.4887 |
0.245 |
|
| 2019 |
Ohashi A, Kataoka M, Kanao S, Iima M, Murata K, Weiland E, Onishi N, Kawai M, Toi M, Togashi K. Diagnostic performance of maximum slope: A kinetic parameter obtained from ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast using k-space weighted image contrast (KWIC). European Journal of Radiology. 118: 285-292. PMID 31324411 DOI: 10.1016/j.ejrad.2019.06.012 |
0.243 |
|
| 2020 |
Kishimoto AO, Kataoka M, Iima M, Honda M, Miyake KK, Ohashi A, Ota R, Kataoka T, Sakurai T, Toi M, Togashi K. The comparison of high-resolution diffusion weighted imaging (DWI) with high-resolution contrast-enhanced MRI in the evaluation of breast cancers. Magnetic Resonance Imaging. 71: 161-169. PMID 32320723 DOI: 10.1016/j.mri.2020.03.007 |
0.242 |
|
| 2022 |
Ota R, Kataoka M, Iima M, Honda M, Ohashi A, Ohno Kishimoto A, Miyake KK, Yamada Y, Takeuchi Y, Toi M, Nakamoto Y. Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis. European Journal of Radiology. 154: 110372. PMID 35667297 DOI: 10.1016/j.ejrad.2022.110372 |
0.241 |
|
| 2010 |
Sugie T, Kassim KA, Takeuchi M, Hashimoto T, Yamagami K, Masai Y, Toi M. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer. Cancers. 2: 713-20. PMID 24281090 DOI: 10.3390/cancers2020713 |
0.241 |
|
| 2002 |
Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe Si S, Miyashita H, Fukumoto M, Toi M, Uchida T. Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. International Journal of Cancer. 97: 631-5. PMID 11807789 DOI: 10.1002/ijc.10105 |
0.241 |
|
| 2017 |
Sugie T, Toi M. Antitumor immunity and advances in cancer immunotherapy. Breast Cancer (Tokyo, Japan). 24: 1-2. PMID 27882505 DOI: 10.1007/s12282-016-0744-x |
0.241 |
|
| 2012 |
Kondo M, Hoshi SL, Ishiguro H, Toi M. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Research and Treatment. 133: 759-68. PMID 22315134 DOI: 10.1007/s10549-012-1979-7 |
0.24 |
|
| 2017 |
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737585. PMID 28580882 DOI: 10.1200/JCO.2017.73.7585 |
0.238 |
|
| 2016 |
Ikeda T, Sugie T, Shimizu A, Toi M. Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. Breast Cancer (Tokyo, Japan). PMID 27568304 DOI: 10.1007/s12282-016-0720-5 |
0.237 |
|
| 2005 |
Matsumoto G, Muta M, Umezawa K, Suzuki T, Misumi K, Tsuruta K, Okamoto A, Toi M. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. International Journal of Oncology. 27: 1247-55. PMID 16211219 |
0.235 |
|
| 2019 |
Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. Breast Cancer (Tokyo, Japan). PMID 30734152 DOI: 10.1007/s12282-019-00952-9 |
0.231 |
|
| 2019 |
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine. 8: 5468-5481. PMID 31361400 DOI: 10.1002/cam4.2423 |
0.231 |
|
| 2010 |
Kumagai Y, Toi M, Kawada K, Kawano T. Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis. Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society. 22: 259-67. PMID 21175477 DOI: 10.1111/j.1443-1661.2010.01010.x |
0.228 |
|
| 2021 |
Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, ... ... Toi M, et al. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers. 13. PMID 34439165 DOI: 10.3390/cancers13164008 |
0.227 |
|
| 2006 |
Bando H, Weich HA, Horiguchi S, Funata N, Ogawa T, Toi M. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncology Reports. 15: 653-9. PMID 16465426 |
0.227 |
|
| 2011 |
Tang Y, Xu F, Tao K, Qian N, Toi M. Clinical applications of sentinel lymph node biopsy in ductal carcinoma in situ of the breast: a dilemma. The Tohoku Journal of Experimental Medicine. 224: 1-5. PMID 21502730 DOI: JST.JSTAGE/tjem/224.1 |
0.226 |
|
| 2017 |
Nakamoto R, Nakamoto Y, Ishimori T, Nishimatsu K, Miyake KK, Kanao S, Iima M, Toi M, Togashi K. Diagnostic performance of a novel dedicated breast PET scanner with C-shaped ring detectors. Nuclear Medicine Communications. 38: 388-395. PMID 28306620 DOI: 10.1097/MNM.0000000000000661 |
0.226 |
|
| 2009 |
Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K, Sakamoto G. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 116: 923-30. PMID 19132986 DOI: 10.1111/j.1600-0463.2008.01122.x |
0.222 |
|
| 2017 |
Iima M, Kataoka M, Kanao S, Onishi N, Kawai M, Ohashi A, Sakaguchi R, Toi M, Togashi K. Intravoxel Incoherent Motion and Quantitative Non-Gaussian Diffusion MR Imaging: Evaluation of the Diagnostic and Prognostic Value of Several Markers of Malignant and Benign Breast Lesions. Radiology. 287: 432-441. PMID 29095673 DOI: 10.1148/radiol.2017162853 |
0.218 |
|
| 2023 |
Ohashi A, Kataoka M, Iima M, Honda M, Ota R, Urushibata Y, Nickel MD, Toi M, Zackrisson S, Nakamoto Y. Comparison of Ultrafast Dynamic Contrast-Enhanced (DCE) MRI with Conventional DCE MRI in the Morphological Assessment of Malignant Breast Lesions. Diagnostics (Basel, Switzerland). 13. PMID 36980417 DOI: 10.3390/diagnostics13061105 |
0.218 |
|
| 2007 |
Yamashiro H, Toi M. [Herceptin (trastuzumab)]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 34: 1173-6. PMID 17687197 |
0.217 |
|
| 2008 |
Yamashiro H, Toi M. [Trastuzumab and Fcgamma]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 1097-100. PMID 18633249 |
0.217 |
|
| 2004 |
Morita S, Toi M, Kobayashi T, Ito Y, Hozumi Y, Ohno S, Iwata H, Sakamoto J. Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. Japanese Journal of Clinical Oncology. 34: 104-6. PMID 15067105 DOI: 10.1093/jjco/hyh016 |
0.217 |
|
| 2021 |
Kishimoto AO, Kataoka M, Iima M, Honda M, Miyake KK, Ohashi A, Ota R, Kataoka T, Sakurai T, Toi M, Togashi K. Evaluation of Malignant Breast Lesions Using High-resolution Readout-segmented Diffusion-weighted Echo-planar Imaging: Comparison with Pathology. Magnetic Resonance in Medical Sciences : Mrms : An Official Journal of Japan Society of Magnetic Resonance in Medicine. 20: 204-215. PMID 32611938 DOI: 10.2463/mrms.mp.2020-0021 |
0.216 |
|
| 2020 |
He C, Kawaguchi K, Toi M. DNA damage repair functions and targeted treatment in breast cancer. Breast Cancer (Tokyo, Japan). PMID 31898156 DOI: 10.1007/s12282-019-01038-2 |
0.215 |
|
| 2018 |
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M. Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. International Cancer Conference Journal. 7: 107-113. PMID 31149526 DOI: 10.1007/s13691-018-0330-5 |
0.211 |
|
| 2019 |
Kitada K, Pu F, Toi M. Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells. Oncology Letters. 17: 1153-1159. PMID 30655877 DOI: 10.3892/ol.2018.9657 |
0.209 |
|
| 2018 |
Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. Plos One. 13: e0198437. PMID 29883453 DOI: 10.1371/journal.pone.0198437 |
0.209 |
|
| 2010 |
Shimbo T, Fukui T, Ishioka C, Okamoto K, Okamoto T, Kameoka S, Sato A, Toi M, Matsui K, Mayumi T, Saji S, Miyazaki M, Takatsuka Y, Hirata K. Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 15: 227-33. PMID 20333432 DOI: 10.1007/s10147-010-0060-y |
0.206 |
|
| 2012 |
Tanaka S, Ueno T, Sato F, Chigusa Y, Kawaguchi-Sakita N, Kawashima M, Fujisawa N, Yoshimura K, Teramukai S, Fujiwara H, Fujita M, Toi M. Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation. The Journal of Clinical Endocrinology and Metabolism. 97: 4182-92. PMID 22948762 DOI: 10.1210/jc.2012-1736 |
0.203 |
|
| 2020 |
Ohashi A, Kataoka M, Iima M, Kanao S, Honda M, Urushibata Y, Nickel MD, Kishimoto AO, Ota R, Toi M, Togashi K. A multiparametric approach to diagnosing breast lesions using diffusion-weighted imaging and ultrafast dynamic contrast-enhanced MRI. Magnetic Resonance Imaging. 71: 154-160. PMID 32302738 DOI: 10.1016/j.mri.2020.04.008 |
0.198 |
|
| 2003 |
Matsumoto G, Nagai S, Muta M, Tsuruta K, Okamoto A, Toi M. Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer. Oncology Reports. 10: 1201-6. PMID 12883681 |
0.197 |
|
| 2003 |
Muta M, Matsumoto G, Hiruma K, Nakashima E, Toi M. Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. Oncology Reports. 10: 1765-9. PMID 14534693 |
0.196 |
|
| 2005 |
Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nature Reviews. Cancer. 5: 297-309. PMID 15803156 DOI: 10.1038/nrc1588 |
0.196 |
|
| 2006 |
Toi M, Iino Y. Who benefits from hormone therapy? Breast Cancer (Tokyo, Japan). 13: 117-22. PMID 16755104 DOI: 10.2325/jbcs.13.117 |
0.191 |
|
| 2013 |
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Ikeda T, Yoshimura K, Niimi M, Shimizu A, Toi M. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Annals of Surgical Oncology. 20: 2213-8. PMID 23429938 DOI: 10.1245/s10434-013-2890-0 |
0.189 |
|
| 2012 |
Chow LW, Toi M. The clinical trials of the Organisation for Oncology and Translational Research (OOTR). The International Journal of Biological Markers. 27: e353-6. PMID 23250776 DOI: 10.5301/JBM.2012.10371 |
0.184 |
|
| 2003 |
Kanzaki A, Nakayama K, Miyashita H, Shirata S, Nitta Y, Oubu M, Higashimoto M, Mutoh M, Mori S, Konno S, Ogawa K, Toi M, Takebayashi Y. Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas. Anticancer Research. 23: 1913-5. PMID 12820478 |
0.183 |
|
| 2017 |
Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Science. PMID 29288540 DOI: 10.1111/cas.13491 |
0.18 |
|
| 2014 |
Hamada S, Hinotsu S, Ishiguro H, Toi M, Kawakami K. Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees. Breast Care (Basel, Switzerland). 8: 282-8. PMID 24415981 DOI: 10.1159/000354249 |
0.175 |
|
| 2006 |
Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood. 107: 716-24. PMID 16174765 DOI: 10.1182/blood-2005-02-0735 |
0.174 |
|
| 2008 |
Ueno T, Elmberger G, Weaver TE, Toi M, Linder S. The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity. Laboratory Investigation; a Journal of Technical Methods and Pathology. 88: 256-63. PMID 18195689 DOI: 10.1038/labinvest.3700718 |
0.172 |
|
| 2023 |
Itagaki K, Miyake KK, Tanoue M, Oishi T, Kataoka M, Kawashima M, Toi M, Nakamoto Y. Feasibility of Dedicated Breast Positron Emission Tomography Image Denoising Using a Residual Neural Network. Asia Oceania Journal of Nuclear Medicine & Biology. 11: 145-157. PMID 37324225 DOI: 10.22038/AOJNMB.2023.71598.1501 |
0.172 |
|
| 2018 |
Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. Magnetic Resonance Imaging. PMID 29545213 DOI: 10.1016/j.mri.2018.03.012 |
0.17 |
|
| 2021 |
Honda M, Kataoka M, Kawaguchi K, Iima M, Miyake KK, Kishimoto AO, Ota R, Ohashi A, Toi M, Nakamoto Y. Subcategory classifications of Breast Imaging and Data System (BI-RADS) category 4 lesions on MRI. Japanese Journal of Radiology. 39: 56-65. PMID 32870440 DOI: 10.1007/s11604-020-01029-w |
0.168 |
|
| 2013 |
Ishiguro H, Kawaguchi K, Nishimura T, Toi M. Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1377-8. PMID 23423751 DOI: 10.1200/JCO.2012.47.2951 |
0.166 |
|
| 2011 |
Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. Journal of Oncology. 2012: 261750. PMID 22007214 DOI: 10.1155/2012/261750 |
0.165 |
|
| 2021 |
Nakamura Y, Takada M, Imamura M, Higami A, Jiaxi H, Fujino M, Nakagawa R, Inagaki Y, Matsumoto Y, Kawaguchi K, Kawashima M, Suzuki E, Toi M. Usefulness and Prospects of Sentinel Lymph Node Biopsy for Patients With Breast Cancer Using the Medical Imaging Projection System. Frontiers in Oncology. 11: 674419. PMID 34123842 DOI: 10.3389/fonc.2021.674419 |
0.164 |
|
| 2022 |
Shirakawa C, Koyasu S, Takada M, Toi M, Nakamoto Y. Unilateral Reduction of 18F-FDG Accumulation in Brown Adipose Tissue by Sympathectomy for Hyperhidrosis. Clinical Nuclear Medicine. 48: 79-80. PMID 36469066 DOI: 10.1097/RLU.0000000000004393 |
0.163 |
|
| 2002 |
Asai G, Yamamoto N, Toi M, Shin E, Nishiyama K, Sekine T, Nomura Y, Takashima S, Kimura M, Tominaga T. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemotherapy and Pharmacology. 49: 468-72. PMID 12107551 DOI: 10.1007/s00280-002-0455-1 |
0.162 |
|
| 2013 |
Idrees AS, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, Minato N, Toi M, Tanaka Y. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Science. 104: 536-42. PMID 23387443 DOI: 10.1111/Cas.12124 |
0.162 |
|
| 2016 |
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. International Journal of Behavioral Medicine. 23: 485-91. PMID 26249725 DOI: 10.1007/s12529-015-9502-2 |
0.157 |
|
| 2007 |
Oikawa T, Onozawa C, Kuranuki S, Igarashi Y, Sato M, Ashino H, Shimamura M, Toi M, Kurakata S. Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo. Cancer Science. 98: 219-25. PMID 17233839 DOI: 10.1111/j.1349-7006.2006.00359.x |
0.156 |
|
| 2005 |
Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, Shimizu S, Yamaguchi T, Matsumoto H. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncology Reports. 13: 405-12. PMID 15706408 |
0.156 |
|
| 2004 |
Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, Gröne HJ, Weich HA. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues International Journal of Cancer. 111: 184-191. PMID 15197769 DOI: 10.1002/Ijc.20211 |
0.155 |
|
| 2009 |
Tsuji W, Inamoto T, Yamashiro H, Ueno T, Kato H, Kimura Y, Tabata Y, Toi M. Adipogenesis induced by human adipose tissue-derived stem cells. Tissue Engineering. Part A. 15: 83-93. PMID 18759663 DOI: 10.1089/ten.tea.2007.0297 |
0.154 |
|
| 2005 |
Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Molecular Cancer Therapeutics. 3: 1485-92. PMID 15542787 |
0.15 |
|
| 2017 |
Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. Cancer Immunology, Immunotherapy : Cii. PMID 28432397 DOI: 10.1007/s00262-017-2002-2 |
0.147 |
|
| 2011 |
Takeda K, Kanao S, Okada T, Ueno T, Toi M, Ishiguro H, Mikami Y, Tanaka S, Togashi K. MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy. European Journal of Radiology. 81: 2148-53. PMID 21664779 DOI: 10.1016/j.ejrad.2011.05.013 |
0.146 |
|
| 2018 |
Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, ... ... Toi M, et al. Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Scientific Reports. 8: 14930. PMID 30297721 DOI: 10.1038/s41598-018-33255-8 |
0.146 |
|
| 2014 |
Nakagawa M, Miyati T, Hayashi T, Kanao S, Taniguchi M, Higashimura K, Toi M, Togashi K. [Triexponential diffusion analysis in invasive ductal carcinoma and fibroadenoma]. Nihon HōShasen Gijutsu Gakkai Zasshi. 70: 199-205. PMID 24647056 DOI: DN/JST.JSTAGE/jjrt/2014_JSRT_70.3.199 |
0.145 |
|
| 2016 |
Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. International Journal of Clinical Oncology. PMID 27864624 DOI: 10.1007/s10147-016-1064-z |
0.144 |
|
| 2006 |
Dewan MZ, Terunuma H, Toi M, Tanaka Y, Katano H, Deng X, Abe H, Nakasone T, Mori N, Sata T, Yamamoto N. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Science. 97: 1381-7. PMID 16995875 DOI: 10.1111/j.1349-7006.2006.00319.x |
0.139 |
|
| 2023 |
Ota R, Kataoka M, Iima M, Honda M, Kishimoto AO, Miyake KK, Yamada Y, Takeuchi Y, Toi M, Nakamoto Y. Evaluation of breast lesions based on modified BI-RADS using high-resolution readout-segmented diffusion-weighted echo-planar imaging and T2/T1-weighted image. Magnetic Resonance Imaging. 98: 132-139. PMID 36608911 DOI: 10.1016/j.mri.2022.12.024 |
0.138 |
|
| 2016 |
Jatoi I, Benson JR, Toi M. De-escalation of axillary surgery in early breast cancer. The Lancet. Oncology. 17: e430-e441. PMID 27733269 DOI: 10.1016/S1470-2045(16)30311-4 |
0.136 |
|
| 2012 |
Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M. Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Medical Oncology (Northwood, London, England). 29: 977-84. PMID 21416157 DOI: 10.1007/s12032-011-9900-5 |
0.126 |
|
| 2024 |
Fujino M, Kawashima M, Yoshifuji H, Nakashima R, Yamada Y, Matsumoto Y, Kawaguchi-Sakita N, Mori Y, Pu F, Yamaguchi A, Kawaguchi K, Takada M, Toi M. Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery. International Cancer Conference Journal. 13: 111-118. PMID 38524641 DOI: 10.1007/s13691-023-00646-2 |
0.12 |
|
| 2024 |
Nakatsuma K, Ozasa N, Ohno M, Ishiguro H, Minami M, Nishi E, Toi M, Ono K, Kimura T. Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer. Journal of Cardiology. PMID 38521118 DOI: 10.1016/j.jjcc.2024.03.005 |
0.12 |
|
| 2024 |
Izawa T, Kobayashi A, Kawashima M, Kawaguchi-Sakita N, Nakakura A, Kataoka Y, Shide K, Mori Y, Yamazaki K, Toi M, Arao H. Quantitative analysis of the effect of docetaxel-induced edema on quality of life in patients with breast cancer and related factors: a prospective cohort study. Bmc Women's Health. 24: 165. PMID 38454375 DOI: 10.1186/s12905-024-03003-4 |
0.12 |
|
| 2024 |
Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, ... ... Toi M, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast Cancer (Tokyo, Japan). PMID 38433181 DOI: 10.1007/s12282-024-01550-0 |
0.12 |
|
| 2024 |
Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry. Breast Cancer (Tokyo, Japan). 31: 185-194. PMID 38319565 DOI: 10.1007/s12282-024-01545-x |
0.12 |
|
| 2018 |
Nagae K, Asao Y, Sudo Y, Murayama N, Tanaka Y, Ohira K, Ishida Y, Otsuka A, Matsumoto Y, Saito S, Furu M, Murata K, Sekiguchi H, Kataoka M, Yoshikawa A, ... ... Toi M, et al. Real-time 3D Photoacoustic Visualization System with a Wide Field of View for Imaging Human Limbs. F1000research. 7: 1813. PMID 30854189 DOI: 10.12688/f1000research.16743.2 |
0.119 |
|
| 2011 |
Tang Y, Liao Y, Kawaguchi-Sakita N, Raut V, Fakhrejahani E, Qian N, Toi M. Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. Journal of Hepato-Biliary-Pancreatic Sciences. 18: 551-8. PMID 21234610 DOI: 10.1007/s00534-010-0368-z |
0.116 |
|
| 2007 |
Asami Y, Kakeya H, Okada G, Toi M, Osada H. RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus. The Journal of Antibiotics. 59: 724-8. PMID 17256472 DOI: 10.1038/ja.2006.97 |
0.115 |
|
| 2005 |
Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice. Oncology. 2: 562-77. PMID 16270097 DOI: 10.1038/ncponc0342 |
0.112 |
|
| 2019 |
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. Journal of the National Cancer Institute. 110: 141-148. PMID 29924336 DOI: 10.1093/jnci/djx178 |
0.111 |
|
| 2010 |
Chen L, Endler A, Uchida K, Horiguchi S, Morizane Y, Iijima O, Toi M, Shibasaki F. Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2alpha expression. Circulation. 122: 910-9. PMID 20713899 DOI: 10.1161/CIRCULATIONAHA.109.931931 |
0.111 |
|
| 2020 |
Mahmud MRA, Ishii K, Lozano CB, Sainz ID, Toi M, Akamatsu S, Fukumoto M, Watanabe M, Takeda S, Ledesma FC, Sasanuma H. TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands. Genes to Cells : Devoted to Molecular & Cellular Mechanisms. PMID 32277721 DOI: 10.1111/gtc.12770 |
0.11 |
|
| 2023 |
Sasaki K, Hayamizu Y, Murakami R, Toi M, Iwai K. Linear ubiquitination-induced necrotic tumor remodeling elicits immune evasion. Febs Letters. 597: 1193-1212. PMID 37060248 DOI: 10.1002/1873-3468.14623 |
0.108 |
|
| 2014 |
Ito R, Morimoto N, Liem PH, Nakamura Y, Kawai K, Taira T, Tsuji W, Toi M, Suzuki S. Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor. Journal of Tissue Engineering and Regenerative Medicine. 8: 1000-8. PMID 22997068 DOI: 10.1002/term.1611 |
0.106 |
|
| 2016 |
Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? Breast Cancer (Tokyo, Japan). 24: 69-78. PMID 26832858 DOI: 10.1007/s12282-016-0668-5 |
0.1 |
|
| 2009 |
Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, Kuroi K, Matsumoto G, Toi M, Nakashima E. Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology. 77: 182-91. PMID 19729975 DOI: 10.1159/000236016 |
0.099 |
|
| 2012 |
Mitsudo Y, Takada M, Toi M. [Multidisciplinary treatment of chemotherapy and surgical therapy]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 70: 571-5. PMID 23350465 |
0.097 |
|
| 2006 |
Muta M, Matsumoto G, Nakashima E, Toi M. Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 264-72. PMID 16397051 DOI: 10.1158/1078-0432.CCR-05-1052 |
0.094 |
|
| 2020 |
Honda M, Kataoka M, Iima M, Miyake KK, Ohashi A, Kishimoto AO, Ota R, Nickel MD, Toi M, Togashi K. Background parenchymal enhancement and its effect on lesion detectability in ultrafast dynamic contrast-enhanced MRI. European Journal of Radiology. 129: 108984. PMID 32534350 DOI: 10.1016/j.ejrad.2020.108984 |
0.089 |
|
| 2004 |
Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M. DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncology Reports. 12: 281-5. PMID 15254689 |
0.086 |
|
| 2004 |
Weich HA, Bando H, Brokelmann M, Baumann P, Toi M, Barleon B, Alitalo K, Sipos B, Sleeman J. Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA Journal of Immunological Methods. 285: 145-155. PMID 14980429 DOI: 10.1016/J.Jim.2003.10.015 |
0.083 |
|
| 2014 |
Tsuda M, Ishiguro H, Yano I, Toi M. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. Journal of the National Cancer Institute. 106. PMID 24906398 DOI: 10.1093/jnci/dju137 |
0.082 |
|
| 2021 |
Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, Fletcher O, Marshall JC, Johnson JG, Wood LS, Toi M, Finn RS, Turner NC, Bartlett CH, Cristofanilli M. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. The Oncologist. PMID 33955129 DOI: 10.1002/onco.13811 |
0.081 |
|
| 2015 |
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer (Tokyo, Japan). PMID 26689708 DOI: 10.1007/s12282-015-0662-3 |
0.081 |
|
| 2023 |
Kusukawa T, Maruo K, Toi M, Yamaura T, Hatano M, Nagao K, Oishi H, Horinouchi Y, Arizumi F, Kishima K, Yoshie N, Tachibana T. Subsequent Domino Osteoporotic Vertebral Fractures Adversely Affect Short-Term Health-Related Quality of Life: A Prospective Multicenter Study. Medicina (Kaunas, Lithuania). 59. PMID 36984591 DOI: 10.3390/medicina59030590 |
0.079 |
|
| 2003 |
Toi M. Proinflammation in human tumor microenvironment: its status and implication. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 8: LE25-6. PMID 12171032 |
0.075 |
|
| 2010 |
Kimura Y, Tsuji W, Yamashiro H, Toi M, Inamoto T, Tabata Y. In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor. Journal of Tissue Engineering and Regenerative Medicine. 4: 55-61. PMID 19830791 DOI: 10.1002/term.218 |
0.073 |
|
| 2022 |
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 28: 4587. PMID 36239018 DOI: 10.1158/1078-0432.CCR-22-2874 |
0.069 |
|
| 2013 |
Chan M, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H. Author's response. Expert Opinion On Therapeutic Targets. 17: 106. PMID 23367523 |
0.069 |
|
| 2005 |
Saeki T, Takashima S, Terashima M, Satoh A, Toi M, Osaki A, Toge T, Ohno S, Nomura N, Fukuyama Y, Koizumi W, Taguchi T. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. International Journal of Clinical Oncology. 10: 51-7. PMID 15729602 DOI: 10.1007/s10147-004-0460-y |
0.068 |
|
| 2016 |
Asao Y, Hashizume Y, Suita T, Nagae KI, Fukutani K, Sudo Y, Matsushita T, Kobayashi S, Tokiwa M, Yamaga I, Fakhrejahani E, Torii M, Kawashima M, Takada M, Kanao S, ... ... Toi M, et al. Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. Journal of Biomedical Optics. 21: 116009. PMID 27893089 DOI: 10.1117/1.JBO.21.11.116009 |
0.066 |
|
| 2023 |
Kozuki S, Kabata M, Sakurai S, Iwaisako K, Nishimura T, Toi M, Yamamoto T, Toyoshima F. Periportal hepatocyte proliferation at midgestation governs maternal glucose homeostasis in mice. Communications Biology. 6: 1226. PMID 38049528 DOI: 10.1038/s42003-023-05614-3 |
0.066 |
|
| 2011 |
Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Toi M, Minato N. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. European Journal of Immunology. 41: 345-55. PMID 21268005 DOI: 10.1002/eji.201040959 |
0.065 |
|
| 2019 |
Tsuge I, Saito S, Yamamoto G, Sekiguchi H, Yoshikawa A, Matsumoto Y, Suzuki S, Toi M. Preoperative vascular mapping for anterolateral thigh flap surgeries: A clinical trial of photoacoustic tomography imaging. Microsurgery. PMID 31713920 DOI: 10.1002/micr.30531 |
0.063 |
|
| 2021 |
Toi M, Velaga R. Next-Generation Clinical Trials and Research with Successful Collaborations. Advances in Experimental Medicine and Biology. 1187: 613-622. PMID 33983603 DOI: 10.1007/978-981-32-9620-6_33 |
0.061 |
|
| 2003 |
Tsuruta K, Okamoto A, Toi M, Saji H, Takahashi T. Impact of selective Glisson transection on survival of hepatocellular carcinoma. Hepato-Gastroenterology. 49: 1607-10. PMID 12397746 |
0.056 |
|
| 2005 |
Toi M, Horiguchi K, Bando H, Saji S, Chow LW. Trastuzumab: updates and future issues. Cancer Chemotherapy and Pharmacology. 56: 94-9. PMID 16273357 DOI: 10.1007/s00280-005-0110-8 |
0.055 |
|
| 2018 |
Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. Plastic and Reconstructive Surgery. 141: 1288-1292. PMID 29697630 DOI: 10.1097/PRS.0000000000004328 |
0.055 |
|
| 2023 |
Hibi T, Yamamoto H, Miyoshi T, Ikeda N, Taketomi A, Ono M, Toi M, Hara H, Nagano H, Kitagawa Y, Mori M. Impact of the coronavirus disease 2019 pandemic on 20 representative surgical procedures in Japan based on the National Clinical Database: annual surveillance of 2021 by the Japan Surgical Society. Surgery Today. PMID 38133829 DOI: 10.1007/s00595-023-02786-7 |
0.049 |
|
| 2008 |
Noguchi S, Toi M. Molecular target therapy: basics and clinical application. Breast Cancer (Tokyo, Japan). 15: 47-8. PMID 18224394 DOI: 10.1007/s12282-007-0019-7 |
0.047 |
|
| 2005 |
Yamashiro H, Toi M. [Basic fibroblast growth factor]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 63: 113-5. PMID 16149466 |
0.046 |
|
| 2003 |
Muta M, Matsumoto G, Hiruma K, Saji S, Nakashima E, Toi M. Impact of vasculogenesis on solid tumor growth in a rat model. Oncology Reports. 10: 1213-8. PMID 12883683 |
0.046 |
|
| 2009 |
Yamashiro H, Toi M. [Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 1067-71. PMID 19620793 |
0.041 |
|
| 2024 |
Toi M, Toshiya T, Noguchi K, Yamanaka H, Kobayashi K, Okubo M, Kishima K, Dai Y. COX2 expression plays a role in spinal cord injury-induced neuropathic pain. Neuroscience Letters. 823: 137663. PMID 38286397 DOI: 10.1016/j.neulet.2024.137663 |
0.04 |
|
| 2013 |
Tsuji W, Inamoto T, Ito R, Morimoto N, Tabata Y, Toi M. Simple and longstanding adipose tissue engineering in rabbits. Journal of Artificial Organs : the Official Journal of the Japanese Society For Artificial Organs. 16: 110-4. PMID 23114565 DOI: 10.1007/s10047-012-0670-4 |
0.04 |
|
| 2010 |
Tsuji W, Yamashiro H, Toi M. [Basic fibroblast growth factor (FGF-2)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 68: 118-20. PMID 20960759 |
0.039 |
|
| 2018 |
Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. Psycho-Oncology. 27: 1840-1846. PMID 29663624 DOI: 10.1002/pon.4736 |
0.038 |
|
| 2013 |
Ishiguro H, Toi M. Colony-stimulating factors for febrile neutropenia. The New England Journal of Medicine. 369: 284. PMID 23863063 DOI: 10.1056/NEJMc1306109 |
0.037 |
|
| 2020 |
Takada M, Toi M. [Ⅱ.POTENT, a Randomized Phase Ⅲ Trial]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 47: 1678-1680. PMID 33342982 |
0.037 |
|
| 2011 |
Sakita-Kawaguchi N, Ueno T, Toi M. [Vascular endothelial growth factor (VEGF)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 106-9. PMID 20960757 |
0.037 |
|
| 2005 |
Bando H, Toi M. [VEGF (vascular endothelial growth factor)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 99-102. PMID 16149462 |
0.037 |
|
| 2013 |
Li W, Saji S, Sato F, Noda M, Toi M. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects. The International Journal of Biological Markers. 28: 117-30. PMID 23787494 DOI: 10.5301/jbm.5000026 |
0.036 |
|
| 2015 |
Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, ... ... Toi M, et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nature Communications. 6: 6153. PMID 25615526 DOI: 10.1038/ncomms7153 |
0.035 |
|
| 2021 |
Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, ... ... Toi M, et al. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). European Journal of Cancer (Oxford, England : 1990). 148: 287-296. PMID 33765513 DOI: 10.1016/j.ejca.2021.01.053 |
0.034 |
|
| 2018 |
Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. Digital artery deformation on movement of the proximal interphalangeal joint. The Journal of Hand Surgery, European Volume. 1753193418807833. PMID 30335597 DOI: 10.1177/1753193418807833 |
0.032 |
|
| 2013 |
Suzuki E, Toi M. [Targeting therapy perspectives]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 620-6. PMID 23350474 |
0.032 |
|
| 2022 |
Shimizu H, Saito S, Yoshikawa A, Sekiguchi H, Tsuge I, Morimoto N, Toi M. Three-dimensional visualization of thoracodorsal artery perforators using photoacoustic imaging. Journal of Plastic, Reconstructive & Aesthetic Surgery : Jpras. PMID 35868973 DOI: 10.1016/j.bjps.2022.06.016 |
0.031 |
|
| 2022 |
Yutaka Y, Kawashima M, Toshi M, Toi M, Date H. Indocyanine green-enhanced thoracoscopic localization of parasternal lymph node: How to do it. Asian Cardiovascular & Thoracic Annals. 2184923221097843. PMID 35471984 DOI: 10.1177/02184923221097843 |
0.03 |
|
| 2023 |
Hida K, Hirano S, Poudel S, Kurashima Y, Stefanidis D, Hashimoto D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Izaki T, Kawamoto S, Otomo Y, Nagai E, Takami H, ... ... Toi M, et al. The degree of satisfaction and level of learning in male and female surgical residents: a nationwide questionnaire survey of graduating residents in Japan. Surgery Today. PMID 37162584 DOI: 10.1007/s00595-023-02683-z |
0.027 |
|
| 2019 |
Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, ... ... Toi M, et al. A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. Surgery Today. PMID 31102022 DOI: 10.1007/s00595-019-01819-4 |
0.025 |
|
| 2012 |
Ren YS, Qian NS, Tang Y, Liao YH, Yang YL, Dou KF, Toi M. Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. Brain Research Bulletin. 87: 244-9. PMID 22075254 DOI: 10.1016/j.brainresbull.2011.10.015 |
0.02 |
|
| 2020 |
Hashimoto D, Poudel S, Hirano S, Kurashima Y, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, ... ... Toi M, et al. Is there disparity between regions and facilities in surgical resident training in Japan? Insights from a national survey. Surgery Today. PMID 32488479 DOI: 10.1007/s00595-020-02037-z |
0.017 |
|
| 2020 |
Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, ... ... Toi M, et al. Are graduating residents sufficiently competent? Results of a national gap analysis survey of program directors and graduating residents in Japan. Surgery Today. PMID 32125504 DOI: 10.1007/s00595-020-01981-0 |
0.013 |
|
| 2021 |
Tsuge I, Yamanaka H, Seo S, Takada M, Katsube M, Sakamoto M, Toi M, Hatano E, Morimoto N. A Novel Real-time Navigation System for Lymphaticovenular Anastomosis Using Projection Mapping with Indocyanine Green Fluorescence. Plastic and Reconstructive Surgery. Global Open. 9: e3758. PMID 34414061 DOI: 10.1097/GOX.0000000000003758 |
0.01 |
|
| 2021 |
Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A. Shimomura. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003477. PMID 33630658 DOI: 10.1200/JCO.20.03477 |
0.01 |
|
| 2007 |
Toi M. What does DNA methylation surrogate? Digestion. 75: 53. PMID 17438354 DOI: 10.1159/000101774 |
0.01 |
|
| Hide low-probability matches. |